VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Marburg Virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. 26S mRNA from VEEV
    2. Lassa nucleoprotein
    3. PagA from Bacillus anthracis
    4. VP24
    5. VP30
    6. VP40
    7. GP from Marburg virus Ci67 (Other)
    8. GP from Marburg virus Ravn (Other)
    9. NP from Marburg virus Musoke (Other)
    10. GP (Protective antigen)
    11. GP from Lake Victoria marburgvirus Musoke (Protective antigen)
    12. GP from Zaire ebolavirus (Protective antigen)
    13. NP (Protective antigen)
    14. NP from Lake Victoria marburgvirus (Protective antigen)
    15. NP from Zaire ebolavirus (Protective antigen)
    16. NP Marburgvirus - Ravn (Protective antigen)
    17. SGP (Protective antigen)
    18. VP35 (Protective antigen)
  3. Vaccine Information
    1. Adenovirus vectors expressing Marburg virus glycoprotein
    2. CAdVa-Filoviruses (EbMarburg viruses)
    3. cAdVaxM(fus)
    4. Heterologous MARV Protein VLP
    5. Irradiated MBGV antigen
    6. Marburg virus DNA prime/boost vaccine DNA/rAd5-GP encoding GP from strain Angola
    7. Marburg virus DNA vaccine DNA-GP encoding GP
    8. Marburg virus DNA vaccine MARV GP encoding GP
    9. Marburg virus glycoprotein expressed by baculovirus recombinants
    10. Marburg Virus Nucleoprotein Vaccine
    11. Marburg virus recombinant vector vaccine CAdVax-Panfilo
    12. Marburg virus recombinant vector vaccine MBGV GP
    13. Marburg virus recombinant vector vaccine MBGV GP/MBGV NP
    14. Marburg virus-like particles
    15. Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
    16. Recombinant VEE Replicons expressing MBGV GP
    17. Recombinant VEE Replicons expressing MBGV NP
    18. VSV-based vaccine expressing MBGV GP
  4. References
I. General Information
1. NCBI Taxonomy ID:
186537
2. Disease:
Hemorrhagic fever
3. Introduction
Marburg was identified in 1967 in Central Africa. It has been known to infect bats, humans, and non-human primates. The virus has caused severe outbreaks of, usually, fatal hemorrhagic fever. In primates, the symtoms are known to be fever, diarrhea, vomiting, coagulation deficits, and severe liver damage. The virus causes a profuse release of inflammatory cytokines, which affects vascular permeability. The excessive bleeding involved sometimes leads to the activation of tissue factor in macrophages and monocytes, as well as a drop in platlet numbers (Mohamadzadeh et al., 2007).
4. Microbial Pathogenesis
The initial targets of infection are generally macrophages, monocytes, and DCs. Filoviruses generally bind to the TREM or C-type lectin receptors on myloid cells. However, since some cells do not express C-lectin or TREM receptors, viral entry may be due to molecules such as heparin-sulphate proteoglycan and folate receptor-α. Data also indicate that the expression of TLR1 (whose signal converges with that of TLR2) was increased on MARV-activated neutrophils (Mohamadzadeh et al., 2007).
5. Host Ranges and Animal Models
The natural host for MARV is known to be bats of Central African origin (Mohamadzadeh et al., 2007).
6. Host Protective Immunity
Filoviruses have been found to disable some of the host IFN pathway, such as the VP35, which prevents the production of type I IFNs, and VP24, which interferes with the abilities of certain molecules to induce antiviral states. IFN is crucial to immune response, as indicated by elevated levels of IFN in the blood even during acute infection. It had also been seen that there is a deficit (virus-induced) in the co-stimulatory properties of infected Dcs, identified by a supressed capacity of the DCs to stimulate allogenic T cells. By affecting either viral exit or entry, cellular proteases could influence viral cellular tropisms and interactions between antibodies and glycoproteins. All host protective immunity observations are also tied with the prevalence of an abundance of cathepsins (Mohamadzadeh et al., 2007).
1. 26S mRNA from VEEV
  • Gene Name : 26S mRNA from VEEV
  • Sequence Strain (Species/Organism) : Venezuelan equine encephalitis virus
  • NCBI Gene ID : 2652924
  • NCBI Protein GI : 9626528
  • Locus Tag : VEEVgp3
  • Genbank Accession : NC_001449.1
  • Protein Accession : NP_040824.1
  • Taxonomy ID : 11036
  • Gene Starting Position : 7562
  • Gene Ending Position : 11329
  • Gene Strand (Orientation) : +
  • Protein Name : structural polyprotein precursor
  • Protein pI : 8.88
  • Protein Weight : 138212.8
  • Protein Length : 1255
  • DNA Sequence : Show Sequence
    >GeneID|2652924 [Venezuelan equine encephalitis virus ] 7562..11329
    atgttcccgttccaaccaatgtatccgatgcagccaatgccctatcgtaacccgttcgcggccccgcgca
    ggccctggttccccagaaccgacccttttctggcgatgcaggtgcaggaattaacccgctcgatggctaa
    cctgacgttcaagcaacgccgggacgcgccacctgaggggccacctgctaagaaacctaagagggaggcc
    ccgcaaaagcaaaaagggggaggccaagggaagaagaagaagaaccaggggaagaagaaggccaagacgg
    ggccgcctaatccgaaggcacagagtggaaacaagaagaagcccaacaagaaaccaggcaagagacagcg
    catggtcatgaaattggaatctgacaagacattcccaattatgctggaagggaagattaacggctacgct
    tgcgtggtcggagggaagttattcaggccgatgcacgtggaaggcaagatcgacaacgacgttctggccg
    cacttaagacgaagaaagcatccaaatatgatcttgagtatgcagatgtgccacagaacatgcgggccga
    tacattcaagtacacccatgagaagccccaaggctattacagctggcatcatggagcagtccaatatgaa
    aatgggcgtttcacggtgccaaaaggagttggggccaagggagacagcggaagacccattctggataatc
    agggacgggtggtcgctattgtgctgggaggtgtgaatgaaggatctaggacagccctttcagtcgtcat
    gtggaacgagaagggagtaactgtgaagtatactccggagaactgcgagcaatggtcactagtgaccact
    atgtgcctgctcgccaatgtgacgttcccatgtgccgaaccaccaatttgctacgacagaaaaccagcag
    agactttggccatgctcagcgttaacgttgacaacccgggctacgatgagctgctggaagcagctgttaa
    gtgccccggaagaaaaaggagatctaccgaggagctgtttaaggagtataagctaacgcgcccttacatg
    gccagatgcatcagatgtgccgttgggagctgccatagtccaatagcaattgaggcagtgaagagcgacg
    ggcacgacggctatgttagacttcagacttcctcgcagtatggcctggattcctctggcaacttaaaggg
    aaggactatgcggtatgatatgcacgggaccattgaagagataccactacatcaagtgtcactccacaca
    tctcgcccgtgtcacattgtggatgggcatggttattttctgcttgctaggtgcccggcaggggactcca
    tcaccatggaatttaagaaaggttcagtcacacactcctgctcagtgccgtatgaagtgaaatttaatcc
    tgtaggcagagaactctacactcatccaccagaacacggagcagagcaagcgtgccaagtctacgcgcac
    gatgcacagaacagaggagcttatgtcgagatgcacctcccgggctcagaagtggacagcagtttgattt
    ccttgagcggcagttcagtcaccgtgacacctcctgtcgggactagcgccttggtgaaatgcaagtgcgg
    cggcacaaagatctccgaaaccatcaacaaggcaaaacagttcagccagtgcacaaagaaggagcagtgc
    agagcatatcgactgcagaatgacaagtgggtgtataattctgacaaactgcccaaagcagcgggagcca
    ccctaaaaggaaaactacacgtcccgttcttgctggcagacggcaaatgcaccgtgcctctagcaccgga
    acctatgataaccttcggtttccgatcagtgtcactgaaactgcaccctaagaatcccacatatctgacc
    actcgccaacttgctgatgagcctcattacacgcacgagctcatatctgaaccagctgttaggaatttta
    ccgtcactgaaaaggggtgggagtttgtatggggaaaccatccgccgaaaaggttttgggcacaggaaac
    agcacccggaaatccacatgggctgccacatgaggtgataactcattattaccacagataccctatgtcc
    accatcctgggtttgtcaatttgcgccgccattgtaaccgtttccgttgcagcgtccacctggctgtttt
    gcaaatccagagtttcgtgcctaactccttaccggctaacacctaacgccaggatgccgctttgcctggc
    cgtgctttgctgcgcccgcactgcccgggccgagaccacctgggagtccttggatcacctatggaacaat
    aaccaacagatgttctggattcaattgctgatccctctggccgccttgattgtagtgactcgcctgctca
    agtgcgtgtgctgtgtagtgccttttttagtcgtggccggcgccgcaggcgccggcgcctacgagcacgc
    gaccacgatgccgagccaagcgggaatctcgtataacaccatagtcaacagagcaggctacgcgccactc
    cctatcagcataacaccaacaaagatcaagctgatacccacagtgaacttggagtacgtcacctgccact
    acaaaacaggaatggattcaccagccatcaaatgctgcggatctcaggaatgtactccaactaacaggcc
    tgatgaacagtgcaaagtcttcacaggggtttacccgttcatgtggggaggtgcatattgcttttgcgac
    actgagaatactcaggtcagcaaggcctacgtaatgaaatctgacgactgccttgcggatcatgctgaag
    catacaaagcgcacacagcctcagtgcaggcgttcctcaacatcacagtgggggaacactctattgtgac
    caccgtgtatgtgaatggagaaactcctgtgaacttcaatggggtcaaactaactgcaggtccactttcc
    acagcttggacaccctttgacagaaaaatcgtgcagtatgccggggagatctataattacgattttcctg
    agtatggggcaggacaaccaggagcatttggagacatacaatccagaacagtctcaagctcagatctgta
    tgccaataccaacctagtgctgcagagacccaaagcaggagcgatccatgtgccatacactcaggcacca
    tcgggttttgagcaatggaagaaagataaagctccgtcattgaaattcaccgcccctttcggatgcgaaa
    tatatacaaaccccattcgcgccgaaaattgtgctgtagggtcaattccattagcctttgacattcccga
    cgccttgttcaccagggtgtcagaaacaccgacactttcagcggccgaatgcactcttaacgagtgcgtg
    tattcatccgactttggcgggatcgccacggtcaagtattcggccagcaagtcaggcaagtgcgcagtcc
    atgtgccatcagggactgctaccctaaaagaagcagcagtcgagctaaccgagcaagggtcggcgaccat
    tcatttctcgaccgcaaatatccacccggagttcaggctccaaatatgcacatcatatgtcacgtgcaaa
    ggtgattgtcaccccccgaaagaccacattgtgacacacccccagtatcacgcccaaacatttacagccg
    cggtgtcaaaaaccgcgtggacgtggttaacatccctgctgggaggatcggccgtaattattataattgg
    cttagtgctggctactattgtggccatgtacgtgctgaccaaccagaaacataattga
  • Protein Sequence : Show Sequence
    >gi|9626528|ref|NP_040824.1| structural polyprotein precursor [Venezuelan equine encephalitis virus ]
    MFPFQPMYPMQPMPYRNPFAAPRRPWFPRTDPFLAMQVQELTRSMANLTFKQRRDAPPEGPPAKKPKREA
    PQKQKGGGQGKKKKNQGKKKAKTGPPNPKAQSGNKKKPNKKPGKRQRMVMKLESDKTFPIMLEGKINGYA
    CVVGGKLFRPMHVEGKIDNDVLAALKTKKASKYDLEYADVPQNMRADTFKYTHEKPQGYYSWHHGAVQYE
    NGRFTVPKGVGAKGDSGRPILDNQGRVVAIVLGGVNEGSRTALSVVMWNEKGVTVKYTPENCEQWSLVTT
    MCLLANVTFPCAEPPICYDRKPAETLAMLSVNVDNPGYDELLEAAVKCPGRKRRSTEELFKEYKLTRPYM
    ARCIRCAVGSCHSPIAIEAVKSDGHDGYVRLQTSSQYGLDSSGNLKGRTMRYDMHGTIEEIPLHQVSLHT
    SRPCHIVDGHGYFLLARCPAGDSITMEFKKGSVTHSCSVPYEVKFNPVGRELYTHPPEHGAEQACQVYAH
    DAQNRGAYVEMHLPGSEVDSSLISLSGSSVTVTPPVGTSALVKCKCGGTKISETINKAKQFSQCTKKEQC
    RAYRLQNDKWVYNSDKLPKAAGATLKGKLHVPFLLADGKCTVPLAPEPMITFGFRSVSLKLHPKNPTYLT
    TRQLADEPHYTHELISEPAVRNFTVTEKGWEFVWGNHPPKRFWAQETAPGNPHGLPHEVITHYYHRYPMS
    TILGLSICAAIVTVSVAASTWLFCKSRVSCLTPYRLTPNARMPLCLAVLCCARTARAETTWESLDHLWNN
    NQQMFWIQLLIPLAALIVVTRLLKCVCCVVPFLVVAGAAGAGAYEHATTMPSQAGISYNTIVNRAGYAPL
    PISITPTKIKLIPTVNLEYVTCHYKTGMDSPAIKCCGSQECTPTNRPDEQCKVFTGVYPFMWGGAYCFCD
    TENTQVSKAYVMKSDDCLADHAEAYKAHTASVQAFLNITVGEHSIVTTVYVNGETPVNFNGVKLTAGPLS
    TAWTPFDRKIVQYAGEIYNYDFPEYGAGQPGAFGDIQSRTVSSSDLYANTNLVLQRPKAGAIHVPYTQAP
    SGFEQWKKDKAPSLKFTAPFGCEIYTNPIRAENCAVGSIPLAFDIPDALFTRVSETPTLSAAECTLNECV
    YSSDFGGIATVKYSASKSGKCAVHVPSGTATLKEAAVELTEQGSATIHFSTANIHPEFRLQICTSYVTCK
    GDCHPPKDHIVTHPQYHAQTFTAAVSKTAWTWLTSLLGGSAVIIIIGLVLATIVAMYVLTNQKHN
  • Related Vaccine(s): Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
2. GP
  • Gene Name : GP
  • Sequence Strain (Species/Organism) : Zaire ebolavirus isolate EBOV/H.sapiens-tc/COD/1995/13625 Kikwit
  • NCBI Protein GI : 1695253
  • Other Database IDs : CDD:110602
    CDD:197367
  • Taxonomy ID : 186538
  • Gene Strand (Orientation) : ?
  • Protein Name : virion spike glycoprotein
  • Protein Length : 676
  • Protein Note : Filovirus glycoprotein; pfam01611
  • Protein Sequence : Show Sequence
    >gi|1695253|gb|AAB37095.1| virion spike glycoprotein [Zaire ebolavirus]
    MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNL
    EGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHK
    VSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPS
    SGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPE
    IDTTIGEWAFWETKKNLTRKIRSEELSFTAVSNRAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAM
    VQVHSQGREAAVSHLTTLATISTSPQPPTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTASDT
    PPATTAAGPLKAENTNTSKGTDLLDPATTTSPQNHSETAGNNNTHHQDTGEESASSGKLGLITNTIAGVA
    GLITGGRRARREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQ
    LANETTQALQLFLRATTELRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDF
    VDKTLPDQGDNDNWWTGWRQWIPAGIGVTGVIIAVIALFCICKFVF
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Marburg virus recombinant vector vaccine CAdVax-Panfilo
3. GP from Lake Victoria marburgvirus Musoke
4. GP from Marburg virus Ci67
  • Gene Name : GP from Marburg virus Ci67
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus
  • NCBI Protein GI : 305862101
  • Locus Tag : AF005735
  • Other Database IDs : CDD:110602
    CDD:197426
    CDD:197370
  • Taxonomy ID : 11269
  • Gene Strand (Orientation) : ?
  • Protein Name : GP
  • Protein Length : 681
  • Protein Note : lethal nonhuman primate, nonlethal guinea pig and mouse MARV variant
  • DNA Sequence : Show Sequence
    >gi|2459879|gb|AF005735.1|AF005735 Marburg virus strain M/Germany/Marburg/1967/Ratayczak glycoprotein precursor (GP) gene, complete cds
    ATGAAGACCACATGTCTCTTTATCAGTCTTATCTTAATCCAAGGGATAAAAACTCTCCCTATTTTAGAGA
    TAGCTAGTAACAATCAACCCCAAAATGTGGATTCGGTATGCTCCGGAACTCTCCAGAAGACAGAAGATGT
    CCATCTGATGGGATTCACACTGAGTGGGCAAAAAGTTGCTGATTCCCCTTTGGAGGCATCCAAGCGATGG
    GCTTTCAGGACAGGTGTACCTCCCAAGAATGTTGAGTATACAGAAGGGGAGGAAGCCAAAACATGCTACA
    ATATAAGTGTAACGGATCCCTCTGGAAAATCCTTGCTGTTGGATCCTCCTACCAACATCCGTGACTATCC
    TAAATGCAAAACTATCCATCATATTCAAGGTCAAAACCCTCATGCACAAGGGATCGCCCTCCATTTGTGG
    GGAGCATTTTTCCTGTATGATCGCATTGCCTCCACAACAATGTACCGAGGCAGAGTCTTCACTGAAGGGA
    ACATAGCAGCTATGATTGTCAATAAGACAGTGCACAAAATGATTTTCTCGAGGCAAGGACAGGGGTACCG
    TCACATGAATCTGACTTCTACTAATAAATATTGGACAAGTAACAATGGAACACAAACGAATGACACTGGA
    TGCTTCGGTGCTCTTCAAGAATACAACTCCACGAAGAATCAAACATGTGCTCCGTCCAAAATACCCTCAC
    CACTGCCCACAGCCCGTCCAGAGATCAAACCCACAAGCACCCCAACTGATGCCACCACACTCAACACCAC
    AGACCCAAACAATGATGATGAGGACCTCATAACATCCGGTTCAGGGTCCGGAGAACAGGAACCCTATACA
    ACTTCAGATGCGGTCACTAAGCAAGGGCTTTCATCAACAATGCCACCCACTCCCTCACCACAACCAAGCA
    CGCCACAGCAAGAAGGAAACAACACAGACCATTCCCAAGGTACTGTGACTGAACCCAACAAAACCAACAC
    AACTGCACAACCGTCCATGCCCCCCCACAACACCACTGCAATCTCTACTAACAACACCTCCAAGAACAAC
    TTCAGCACCCTCTCTGTATCACTACAAAACACCACCAATTACGACACACAGAGCACAGCCACTGAAAATG
    AACAAACCAGTGCCCCCTCGAAAACAACCCTGCCTCCAACAGGAAATCTTACCACAGCAAAGAGCACAAA
    CAACACGAAAGGCCCCACCACAACGGCACCAAATATGACAAATGGGCATTTAACCAGTCCCTCCCCCACC
    CCCAACCCGACCACACAACATCTTGTATATTTCAGAAAGAAACGAAGTATCCTCTGGAGGGAAGGCGACA
    TGTTTCCTTTTCTGGACGGGTTAATAAATGCTCCAATTGATTTTGATCCAGTTCCAAATACAAAGACGAT
    CTTTGATGAATCTTCTAGTTCTGGTGCTTCGGCTGAGGAAGATCAACATGCCTCCCCCAATATCAGTTTA
    ACTTTATCCTATTTTCCTAATATAAATGAAAACACTGCCTACTCTGGAGAAAATGAGAACGATTGTGATG
    CAGAGTTAAGAATTTGGAGCGTTCAGGAGGATGACCTGGCAGCAGGGCTCAGTTGGATACCGTTTTTTGG
    CCCTGGAATCGAAGGACTTTATACTGCTGGTTTAATTAAAAACCAAAACAATTTGGTCTGCAGGTTGAGG
    CGTCTAGCCAATCAAACTGCCAAATCCTTGGAACTCTTATTAAGAGTCACAACCGAGGAAAGGACATTTT
    CCTTAATTAATAGACATGCCATTGACTTTCTACTCACAAGGTGGGGAGGAACATGCAAAGTGCTTGGACC
    TGATTGTTGCATTGGAATAGAAGACTTGTCCAGGAATATTTCGGAACAAATTGACCAAATCAAAAAAGAT
    GAACAAAAAGAGGGGACTGGTTGGGGTCTAGGTGGTAAATGGTGGACATCCGACTGGGGTGTTCTTACTA
    ACTTGGGCATTTTGCTACTATTATCCATAGCTGTCTTGATTGCTCTATCCTGTATTTGTCGTATCTTTAC
    CAAATATATCGGGTAA
  • Protein Sequence : Show Sequence
    >gi|305862101|gb|ADM72998.1| GP [Marburg marburgvirus]
    MKTTCLFISLILIQGIKTLPILEIASNNQPQNVDSVCSGTLQKTEDVHLMGFTLSGQKVADSPLEASKRW
    AFRTGVPPKNVEYTEGEEAKTCYNISVTDPSGKSLLLDPPTNIRDYPKCKTIHHIQGQNPHAQGIALHLW
    GAFFLYDRIASTTMYRGRVFTEGNIAAMIVNKTVHKMIFSRQGQGYRHMNLTSTNKYWTSNNGTQTNDTG
    CFGALQEYNSTKNQTCAPSKIPSPLPTARPEIKPTSTPTDATTLNTTDPNNDDEDLITSGSGSGEQEPYT
    TSDAVTKQGLSSTMPPTPSPQPSTPQQEGNNTDHSQGTVTEPNKTNTTAQPSMPPHNTTAISTNNTSKNN
    FSTLSVSLQNTTNYDTQSTATENEQTSAPSKTTLPPTGNLTTAKSTNNTKGPTTTAPNMTNGHLTSPSPT
    PNPTTQHLVYFRKKRSILWREGDMFPFLDGLINAPIDFDPVPNTKTIFDESSSSGASAEEDQHASPNISL
    TLSYFPNINENTAYSGENENDCDAELRIWSVQEDDLAAGLSWIPFFGPGIEGLYTAGLIKNQNNLVCRLR
    RLANQTAKSLELLLRVTTEERTFSLINRHAIDFLLTRWGGTCKVLGPDCCIGIEDLSRNISEQIDQIKKD
    EQKEGTGWGLGGKWWTSDWGVLTNLGILLLLSIAVLIALSCICRIFTKYIG
  • Molecule Role : Other
  • Related Vaccine(s): Adenovirus vectors expressing Marburg virus glycoprotein , CAdVa-Filoviruses (EbMarburg viruses) , cAdVaxM(fus) , Marburg virus recombinant vector vaccine CAdVax-Panfilo
5. GP from Marburg virus Ravn
  • Gene Name : GP from Marburg virus Ravn
  • Sequence Strain (Species/Organism) : M/Kenya/Kitum Cave/1987/Ravn
  • NCBI Protein GI : 2459878
  • Other Database IDs : CDD:110602
    CDD:197426
    CDD:197370
  • Taxonomy ID : 11269
  • Gene Strand (Orientation) : ?
  • Protein Name : glycoprotein precursor
  • Protein Length : 681
  • Protein Note : Filovirus glycoprotein; pfam01611
  • DNA Sequence : Show Sequence
    >gi|2459877|gb|AF005734.1|AF005734 Marburg virus strain M/Kenya/Kitum Cave/1987/Ravn glycoprotein precursor (GP) gene, complete cds
    ATGAAGACCATATATTTTCTGATTAGTCTCATTTTAATCCAAAGTATAAAAACTCTCCCTGTTTTAGAAA
    TTGCTAGTAACAGCCAACCTCAAGATGTAGATTCAGTGTGCTCCGGAACCCTCCAAAAGACAGAAGATGT
    TCATCTGATGGGATTTACACTGAGTGGGCAAAAAGTTGCTGATTCCCCTTTGGAAGCATCTAAACGATGG
    GCTTTCAGGACAGGTGTTCCTCCCAAGAACGTTGAGTATACGGAAGGAGAAGAAGCCAAAACATGTTACA
    ATATAAGTGTAACAGACCCTTCTGGAAAATCCTTGCTGCTGGATCCTCCCAGTAATATCCGCGATTACCC
    TAAATGTAAAACTGTTCATCATATTCAAGGTCAAAACCCTCATGCACAGGGGATTGCCCTCCATTTGTGG
    GGGGCATTTTTCTTGTATGATCGCGTTGCCTCTACAACAATGTACCGAGGCAAGGTCTTCACTGAAGGAA
    ATATAGCAGCTATGATTGTTAATAAGACAGTTCACAGAATGATTTTTTCTAGGCAAGGACAAGGTTATCG
    TCACATGAACTTGACCTCCACCAATAAATATTGGACAAGCAGCAATGAAACGCAGAGAAATGATACGGGA
    TGTTTTGGCATCCTCCAAGAATACAACTCCACAAACAATCAAACATGCCCTCCATCTCTTAAACCTCCAT
    CCCTGCCCACAGTAACTCCGAGCATTCACTCTACAAATACTCAAATTAATACTGCTAAATCTGGAACTAT
    GAACCCAAGTAGCGACGATGAGGACCTTATGATTTCCGGCTCAGGATCTGGAGAACAGGGGCCCCACACA
    ACTCTTAATGTAGTCACTGAACAGAAACAATCGTCAACAATATTGTCCACTCCTTCACTACATCCAAGCA
    CCTCACAACATGAGCAAAACAGTACGAATCCTTCCCGACATGCTGTAACTGAGCACAATGGAACCGACCC
    AACAACACAACCAGCAACGCTCCTCAACAATACTAATACAACTCCCACCTATAACACTCTCAAGTACAAC
    CTCAGTACTCCTTCCCCTCCAACCCGCAACATCACCAATAATGATACACAACGTGAACTAGCAGAAAGCG
    AACAAACCAATGCTCAGTTGAACACAACTCTAGATCCAACAGAAAATCCCACCACAGGACAAGACACCAA
    CAGCACAACCAACATCATCATGACGACATCAGATATAACAAGCAAACACCCCACAAATTCTTCTCCGGAT
    TCTAGTCCGACAACCCGCCCTCCTATATACTTTAGAAAGAAACGAAGCATTTTCTGGAAAGAAGGTGATA
    TATTCCCGTTTTTAGATGGGTTAATAAATACTGAAATTGATTTTGATCCAATCCCAAACACAGAAACAAT
    CTTTGATGAATCTCCCAGCTTTAATACTTCAACTAATGAGGAACAACACACTCCCCCGAATATCAGTTTA
    ACTTTCTCTTATTTTCCTGATAAAAATGGAGATACTGCCTACTCTGGGGAAAACGAGAATGATTGTGATG
    CAGAGTTGAGGATTTGGAGTGTGCAGGAGGACGATTTGGCGGCAGGGCTTAGCTGGATACCATTTTTTGG
    CCCTGGAATCGAAGGACTCTATACTGCCGGTTTAATCAAAAATCAGAACAATTTAGTTTGTAGGTTGAGG
    CGCTTAGCTAATCAAACTGCTAAATCCTTGGAGCTCTTGTTAAGGGTCACAACCGAGGAAAGGACATTTT
    CCTTAATCAATAGGCATGCAATTGACTTTTTGCTTACGAGGTGGGGCGGAACATGCAAGGTGCTAGGACC
    TGATTGTTGCATAGGAATAGAAGATCTATCTAAAAATATCTCAGAACAAATCGACAAAATCAGAAAGGAT
    GAACAAAAGGAGGAAACTGGCTGGGGTCTAGGTGGCAAATGGTGGACATCTGACTGGGGTGTTCTCACCA
    ATTTGGGCATCCTGCTACTATTATCTATAGCTGTTCTGATTGCTCTGTCCTGTATCTGTCGTATCTTCAC
    TAAATACATTGGATGA
  • Protein Sequence : Show Sequence
    >gi|2459878|gb|AAC40459.1| glycoprotein precursor [Marburg marburgvirus]
    MKTIYFLISLILIQSIKTLPVLEIASNSQPQDVDSVCSGTLQKTEDVHLMGFTLSGQKVADSPLEASKRW
    AFRTGVPPKNVEYTEGEEAKTCYNISVTDPSGKSLLLDPPSNIRDYPKCKTVHHIQGQNPHAQGIALHLW
    GAFFLYDRVASTTMYRGKVFTEGNIAAMIVNKTVHRMIFSRQGQGYRHMNLTSTNKYWTSSNETQRNDTG
    CFGILQEYNSTNNQTCPPSLKPPSLPTVTPSIHSTNTQINTAKSGTMNPSSDDEDLMISGSGSGEQGPHT
    TLNVVTEQKQSSTILSTPSLHPSTSQHEQNSTNPSRHAVTEHNGTDPTTQPATLLNNTNTTPTYNTLKYN
    LSTPSPPTRNITNNDTQRELAESEQTNAQLNTTLDPTENPTTGQDTNSTTNIIMTTSDITSKHPTNSSPD
    SSPTTRPPIYFRKKRSIFWKEGDIFPFLDGLINTEIDFDPIPNTETIFDESPSFNTSTNEEQHTPPNISL
    TFSYFPDKNGDTAYSGENENDCDAELRIWSVQEDDLAAGLSWIPFFGPGIEGLYTAGLIKNQNNLVCRLR
    RLANQTAKSLELLLRVTTEERTFSLINRHAIDFLLTRWGGTCKVLGPDCCIGIEDLSKNISEQIDKIRKD
    EQKEETGWGLGGKWWTSDWGVLTNLGILLLLSIAVLIALSCICRIFTKYIG
  • Molecule Role : Other
  • Related Vaccine(s): Adenovirus vectors expressing Marburg virus glycoprotein , CAdVa-Filoviruses (EbMarburg viruses) , cAdVaxM(fus) , Marburg virus DNA vaccine MARV GP encoding GP , Marburg virus recombinant vector vaccine CAdVax-Panfilo , Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
6. GP from Zaire ebolavirus
  • Gene Name : GP from Zaire ebolavirus
  • Sequence Strain (Species/Organism) : Zaire ebolavirus (ZEBOV)
  • VO ID : VO_0010932
  • NCBI Protein GI : 21702651
  • Locus Tag : AAM76034
  • Other Database IDs : CDD:110602
  • Taxonomy ID : 186538
  • Gene Strand (Orientation) : ?
  • Protein Name : surface glycoprotein GP precursor
  • Protein Length : 676
  • Protein Note : subtype: Zaire; biotype: mouse adapted variant
  • Protein Sequence : Show Sequence
    >gi|21702651|gb|AAM76034.1| surface glycoprotein GP precursor [Zaire ebolavirus]
    MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRPVGLNL
    EGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHK
    VSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPS
    SGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLEPRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPE
    IDTTIGEWAFWETKKNLTRKIRSEELSFTVVSNGAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAM
    VQVHSQGREAAVSHLTTLATISTSPQSLTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTASDT
    PSATTAAGPPKAENTNTSKSTDFLDPATTTSPQNHSETAGNNNTHHQDTGEESASSGKLGLITNTIAGVA
    GLITGGRRTRREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQ
    LANETTQALQLFLRATTELRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDF
    VDKTLPDQGDNDNWWTGWRQWIPAGIGVTGVIIAVIALFCICKFVF
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
7. Lassa nucleoprotein
  • Gene Name : Lassa nucleoprotein
8. NP
  • Gene Name : NP
  • Sequence Strain (Species/Organism) : Zaire ebolavirus isolate EBOV/H.sapiens-tc/COD/1995/13709 Kikwit
  • NCBI Protein GI : 436409420
  • Other Database IDs : CDD:147601
  • Taxonomy ID : 186538
  • Gene Strand (Orientation) : ?
  • Protein Name : NP
  • Protein Length : 739
  • Protein Note : Ebola nucleoprotein; pfam05505
  • Protein Sequence : Show Sequence
    >gi|436409420|gb|AGB56818.1| NP [Zaire ebolavirus]
    MDSRPQKVWMTPSLTESDMDYHKILTAGLSVQQGIVRQRVIPVYQVNNLEEICQLIIQAFEAGVDFQESA
    DSFLLMLCLHHAYQGDYKLFLESGAVKYLEGHGFRFEVKKRDGVKRLEELLPAVSSGKNIKRTLAAMPEE
    ETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHAEQGLIQYPTAWQSVGHMMVIFRLMRTNFLI
    KFLLIHQGMHMVAGHDANDAVISNSVAQARFSGLLIVKTVLDHILQKTERGVRLHPLARTAKVKNEVNSF
    KAALSSLAKHGEYAPFARLLNLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEA
    EKQLQQYAESRELDHLGLDDQEKKILMNFHQKKNEISFQQTNAMVTLRKERLAKLTEAITAASLPKTSGH
    YDDDDDIPFPGPINDDDNPGHQDDDPTDSQDTTIPDVVVDPDDGSYGEYQSYSENGMNAPDDLVLFDLDE
    DDEDTKPVPNRSTKGGQQKNSQKGQHTEGRQTQSRPTQNVPGPHRTIHHASAPLTDNDRRNEPSGSTSPR
    MLTPINEEADPLDDADDETSSLPPLESDDEEQDRDGTSNRTPTVAPPAPVYRDHSEKRELPQDEQQDQDH
    TQEARNQDSDNTQPEHSFEEMYRHILRSQGPFDAVLYYHMMKDEPVVFSTSDGKEYTYPDSLEEEYPPWL
    TEKEAMNEENRFVTLDGQQFYWPVMNHKNKFMAILQHHQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Marburg virus recombinant vector vaccine CAdVax-Panfilo
9. NP from Lake Victoria marburgvirus
  • Gene Name : NP from Lake Victoria marburgvirus
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus
  • VO ID : VO_0011163
  • NCBI Protein GI : 332181
  • Other Database IDs : CDD:147601
  • Taxonomy ID : 11269
  • Gene Strand (Orientation) : ?
  • Protein Name : nucleoprotein
  • Protein Length : 695
  • Protein Note : Ebola nucleoprotein; pfam05505
  • Protein Sequence : Show Sequence
    >gi|332181|gb|AAA46563.1| nucleoprotein [Lake Victoria marburgvirus]
    MDLHSLLELGTKPTAPHVRNKKVILFDTNHQVSICNQIIDAINSGIDLGDLLEGGLLTLCVEHYYNSDKD
    KFNTSPVAKYLRDAGYEFDVIKNADATRFLDVSPNEPHYSPLILALKTLESTESQRGRIGLFLSFCSLFL
    PKLVVGDRASIEKALRQVTVHQEQGIVTYPNHWLTTGHMKVIFGILRSSFILKFVLIHQGVNLVTGHDAY
    DSIISNSVGQTRFSGLLIVKTVLEFILQKTDSGVTLHPLVRTSKVKNEVASFKQALSNLARHGEYAPFAR
    VLNLSGINNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAAHDAEVKLQRRHEHQEIQAIAE
    DDEERKILEQFHLQKTEITHSQTLAVLSQKREKLARLAAEIENNIVEDQGFKQSQNRVSQSFLNDPTPVE
    VTVQARPMNRPTALPPPVDDKIEHESTEDSSSSSSFVDLNDPFALLNEDEDTLDDSVMIPGTTSREFQGI
    PEPPRQSQDLNNSQGKQEDESTNRIKKQFLRYQELPPVQEDDESEYTTDSQESIDQPGSDNEQGVDLPPP
    PLYAQEKRQDPIQHPAANPQDPFGSIGDVNGDILEPIRSPSSPSAPQEDTRMREAYELSPDFTNDEDNQQ
    NWPQRVVTKKGRTFLYPNDLLQTNPPESLITALVEEYQNPVSAKELQADWPDMSFDERRHVAMNL
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Nonhuman primates (cynomolgus macaques) were inoculated with VEE replicons expressing MBGV GP and/or NP and challenged with MGBV. MBGV NP afforded incomplete (partial) protection, sufficient to prevent death but not disease in two of three macaques (Hevey et al., 1998).
  • Related Vaccine(s): Marburg Virus Nucleoprotein Vaccine , Marburg virus recombinant vector vaccine MBGV GP
10. NP from Marburg virus Musoke
  • Gene Name : NP from Marburg virus Musoke
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus - Musoke
  • NCBI Protein GI : 60624
  • Locus Tag : DQ217792
  • Other Database IDs : CDD:147601
    CDD:163153
    GOA:P27588
    InterPro: IPR008609
    UniProtKB/UniProt: P27588
  • Taxonomy ID : 33727
  • Gene Strand (Orientation) : ?
  • Protein Name : nucleoprotein
  • Protein Length : 692
  • Protein Note : Ebola nucleoprotein; pfam05505
  • DNA Sequence : Show Sequence
    >gi|77543426:49-2844 Lake Victoria marburgvirus - Musoke from Kenya, complete genome
    GAAGAATATTAACATTGACATTGAGACTTGTCAGTCTGTTAATATTCTTGAAGAGATGGATTTACACAGT
    TTGTTGGAGTTGGGTACAAAACCCACTGCCCCTCATGTTCGTAATAAGAAAGTGATATTATTTGACACAA
    ATCATCAGGTTAGTATCTGTAATCAGATAATAGATGCAATAAACTCAGGGATTGATCTTGGAGATCTCCT
    AGAAGGGGGTTTGCTGACGTTGTGTGTTGAGCATTACTATAATTCTGATAAGGATAAATTCAACACAAGT
    CCTATCGCGAAGTACTTACGTGATGCGGGCTATGAATTTGATGTCATCAAGAATGCAGATGCAACCCGCT
    TTCTGGATGTGATTCCTAATGAACCTCATTACAGCCCTTTAATTCTAGCCCTTAAGACATTGGAAAGTAC
    TGAATCTCAGAGGGGGAGAATTGGGCTCTTTTTATCATTTTGCAGTCTTTTCCTCCCAAAACTTGTCGTC
    GGAGACCGAGCTAGTATCGAAAAGGCTTTAAGACAAGTAACAGTGCATCAAGAACAGGGGATCGTCACAT
    ACCCTAATCATTGGCTTACCACAGGCCACATGAAAGTAATTTTCGGGATTTTGAGGTCCAGCTTCATTTT
    AAAGTTTGTGTTGATTCATCAAGGAGTAAATTTGGTGACAGGTCATGATGCCTATGACAGTATCATTAGT
    AATTCAGTAGGTCAAACTAGATTCTCAGGACTTCTTATCGTGAAAACAGTTCTCGAGTTCATCTTGCAAA
    AAACTGATTCAGGGGTGACACTACATCCTTTGGTGCGGACCTCCAAAGTAAAAAATGAAGTTGCTAGTTT
    CAAGCAGGCGTTGAGCAACCTAGCCCGACATGGGGAATACGCACCATTTGCACGGGTTCTGAATTTATCA
    GGGATTAACAACCTCGAACATGGACTCTATCCTCAGCTTTCAGCAATTGCGCTGGGTGTGGCAACAGCAC
    ACGGCAGTACATTGGCTGGTGTCAATGTTGGCGAACAATATCAACAACTACGAGAGGCGGCACATGATGC
    GGAAGTAAAACTACAAAGGCGACATGAACATCAGGAAATTCAAGCTATTGCCGAGGATGACGAGGAAAGG
    AAGATATTAGAACAATTCCACCTTCAGAAAACTGAAATCACACACAGTCAGACACTAGCCGTCCTCAGCC
    AGAAACGAGAAAAATTAGCTCGTCTCGCTGCAGAAATTGAAAACAATATTGTGGAAGATCAGGGATTTAA
    GCAATCACAGAATCGGGTGTCACAGTCGTTTTTGAATGACCCTACACCTGTGGAAGTAACGGTTCAAGCC
    AGGCCCATGAATCGACCAACTGCTCTGCCTCCCCCAGTTGACGACAAGATTGAGCATGAATCTACAGAAG
    ATAGCTCTTCTTCAAGTAGCTTTGTTGACTTGAATGATCCATTTGCACTGCTGAATGAGGACGAGGATAC
    TCTTGATGACAGTGTCATGATCCCGGGCACAACATCGAGAGAATTTCAAGGGATTCCTGAACCGCCAAGA
    CAATCCCAAGACCTCAATAACAGCCAAGGAAAGCAGGAAGATGAATCCACAAATCCGATTAAGAAACAGT
    TTCTGAGATATCAAGAATTGCCTCCTGTTCAAGAGGATGATGAATCGGAATACACAACTGACTCTCAAGA
    AAGCATCGACCAACCAGGATCCGACAATGAACAAGGAGTTGATCTTCCACCTCCTCCGTTGTACGCTCAG
    GAAAAAAGACAGGACCCAATACAGCACCCAGCAGCAAACCCTCAGGATCCCTTCGGCAGTATTGGTGATG
    TAAATGGTGATATCTTAGAACCTATAAGATCACCTTCTTCACCATCTGCTCCTCAGGAAGACACAAGGAT
    GAGGGAAGCCTATGAATTGTCGCCTGATTTCACAAATGATGAGGATAATCAGCAGAATTGGCCACAAAGA
    GTGGTGACAAAGAAGGGTAGAACTTTCCTTTATCCTAATGATCTTCTGCAAACAAATCCTCCAGAGTCAC
    TTATAACAGCCCTCGTTGAGGAATACCAAAATCCTGTCTCAGCTAAGGAGCTTCAAGCAGATTGGCCCGA
    CATGTCATTTGATGAAAGGAGACATGTTGCGATGAACTTGTAGTCCAGATAACACAGCACGGTTACTCAC
    TTATCTATTTTGATATGACTCATCCTCAGATCACAGCAATCAAATTTATTTGAATATTTGAACCACCTTT
    TAGTATCCTATTACTTGTTACTATTGTGTGAGACAACATAAGCCATCAAATAACAATCACGGGCAAGGAC
    TGGGCATACTATGGTGGTCTTAGAGCATTGTCCAGTGCTACAAATTCTTTTTTCAATTGCTATAATTATA
    CAACTACAAACCTCCATACATTTGCCGCAACACTGTAATCAACACTGCTGTATCTCTTCTTCAAGCCATC
    TGATTTAACTTAATAAACATGACTTGATTCAAAGAATATACTGACAATGTTACTGTTTGAATTTCTCAAG
    TGGTGCACTATCCTACTGTTTTGCTCAGCTTAGTATATTGTAATATGTAAGTGGACTCTCCCCTTCTCCT
    CTCGTGTATTCTTTATAAATCACTTACTTGATAGAATGTCGAGTCTACTGGTTTGGAGTTTCCTTACTCT
    AATGGATGTAATAATTAACTGTTGGCCTAGATGATAACAGATATGAGGTTATATAATTACTCATAGTGTA
    AAGTATAATTCTTACCTCTGTTTCTTCTGTTTTCCCTTTCTTTTATAATATGCCAATTAAGAAAAA
  • Protein Sequence : Show Sequence
    >gi|60624|emb|CAA78114.1| nucleoprotein [Marburg virus - Musoke, Kenya, 1980]
    MDLHSLLELGTKPTAPHVRNKKVILFDTNHQVSICNQIIDAINSGIDLGDLLEGGLLTLCVEHYYNSDKD
    KFNTSPVAKYLRDAGYEFDVIKNADATRFLDVSPNEPHYSPLILALKTLESTESQRGRIGLFLSFCSLFL
    PKLVVGDRASIEKALRQVTVHQEQGIVTYPNHWLTTGHMKVIFGILRSSFILKFVLIHQGVNLVTGHDAY
    DSIISNSVGQTRFSGLLIVKTVLEFILQKTDSGVTLHPLVRTSKVKNEVASFKQALSNLARHGEYAPFAR
    VLNLSGINNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAAHDAEVKLQRRHEHQEIQAIAE
    DDEERKILEQFHLQKTEITHSQTLAVLSQKREKLARLAAEIENNIVEDQGFKQSQNRVSQSFLNDPTPVE
    VTVQARPMNRPTALPPPVDDKIEHESTEDSSSSSSFVDLNDPFALLNEDEDTLDDSVMIPGTTSREFQGI
    PEPPRQSQDLNNSQGKQEDESTNRIKKQFLRYQELPPVQEDDESEYTTDSQESIDQPGSDNEQGVDLPPP
    PLYAQEKRQDPIQHPAANPQDPFGSIGDVNGDILEPIRSPSSPSAPQEDTRMREAYELSPDFTNDEDNQQ
    NWPQRVVTKKGRTFLYPNDLLQTNPPESLITALVEEYQNPVSAKELQADWPDMSFDEGDMLR
  • Molecule Role : Other
  • Related Vaccine(s): Marburg virus glycoprotein expressed by baculovirus recombinants , Marburg virus recombinant vector vaccine CAdVax-Panfilo , Marburg virus recombinant vector vaccine MBGV GP/MBGV NP , Recombinant VEE Replicons expressing MBGV NP
11. NP from Zaire ebolavirus
  • Gene Name : NP from Zaire ebolavirus
  • Sequence Strain (Species/Organism) : Zaire ebolavirus
  • VO ID : VO_0010931
  • NCBI Gene ID : 911830
  • NCBI Protein GI : 10314000
  • Locus Tag : ZEBOVgp1
  • Genbank Accession : L11365
  • Protein Accession : NP_066243
  • Taxonomy ID : 186538
  • Gene Starting Position : 55
  • Gene Ending Position : 3025
  • Gene Strand (Orientation) : +
  • Protein Name : mRNA
  • Protein pI : 4.77
  • Protein Weight : 79118.19
  • Protein Length : 739
  • DNA Sequence : Show Sequence
    >gi|10313991:55-3025 Zaire ebolavirus, complete genome
    TGAGGAAGATTAATAATTTTCCTCTCATTGAAATTTATATCGGAATTTAAATTGAAATTGTTACTGTAAT
    CACACCTGGTTTGTTTCAGAGCCACATCACAAAGATAGAGAACAACCTAGGTCTCCGAAGGGAGCAAGGG
    CATCAGTGTGCTCAGTTGAAAATCCCTTGTCAACACCTAGGTCTTATCACATCACAAGTTCCACCTCAGA
    CTCTGCAGGGTGATCCAACAACCTTAATAGAAACATTATTGTTAAAGGACAGCATTAGTTCACAGTCAAA
    CAAGCAAGATTGAGAATTAACCTTGGTTTTGAACTTGAACACTTAGGGGATTGAAGATTCAACAACCCTA
    AAGCTTGGGGTAAAACATTGGAAATAGTTAAAAGACAAATTGCTCGGAATCACAAAATTCCGAGTATGGA
    TTCTCGTCCTCAGAAAATCTGGATGGCGCCGAGTCTCACTGAATCTGACATGGATTACCACAAGATCTTG
    ACAGCAGGTCTGTCCGTTCAACAGGGGATTGTTCGGCAAAGAGTCATCCCAGTGTATCAAGTAAACAATC
    TTGAAGAAATTTGCCAACTTATCATACAGGCCTTTGAAGCAGGTGTTGATTTTCAAGAGAGTGCGGACAG
    TTTCCTTCTCATGCTTTGTCTTCATCATGCGTACCAGGGAGATTACAAACTTTTCTTGGAAAGTGGCGCA
    GTCAAGTATTTGGAAGGGCACGGGTTCCGTTTTGAAGTCAAGAAGCGTGATGGAGTGAAGCGCCTTGAGG
    AATTGCTGCCAGCAGTATCTAGTGGAAAAAACATTAAGAGAACACTTGCTGCCATGCCGGAAGAGGAGAC
    AACTGAAGCTAATGCCGGTCAGTTTCTCTCCTTTGCAAGTCTATTCCTTCCGAAATTGGTAGTAGGAGAA
    AAGGCTTGCCTTGAGAAGGTTCAAAGGCAAATTCAAGTACATGCAGAGCAAGGACTGATACAATATCCAA
    CAGCTTGGCAATCAGTAGGACACATGATGGTGATTTTCCGTTTGATGCGAACAAATTTTCTGATCAAATT
    TCTCCTAATACACCAAGGGATGCACATGGTTGCCGGGCATGATGCCAACGATGCTGTGATTTCAAATTCA
    GTGGCTCAAGCTCGTTTTTCAGGCTTATTGATTGTCAAAACAGTACTTGATCATATCCTACAAAAGACAG
    AACGAGGAGTTCGTCTCCATCCTCTTGCAAGGACCGCCAAGGTAAAAAATGAGGTGAACTCCTTTAAGGC
    TGCACTCAGCTCCCTGGCCAAGCATGGAGAGTATGCTCCTTTCGCCCGACTTTTGAACCTTTCTGGAGTA
    AATAATCTTGAGCATGGTCTTTTCCCTCAACTATCGGCAATTGCACTCGGAGTCGCCACAGCACACGGGA
    GTACCCTCGCAGGAGTAAATGTTGGAGAACAGTATCAACAACTCAGAGAGGCTGCCACTGAGGCTGAGAA
    GCAACTCCAACAATATGCAGAGTCTCGCGAACTTGACCATCTTGGACTTGATGATCAGGAAAAGAAAATT
    CTTATGAACTTCCATCAGAAAAAGAACGAAATCAGCTTCCAGCAAACAAACGCTATGGTAACTCTAAGAA
    AAGAGCGCCTGGCCAAGCTGACAGAAGCTATCACTGCTGCGTCACTGCCCAAAACAAGTGGACATTACGA
    TGATGATGACGACATTCCCTTTCCAGGACCCATCAATGATGACGACAATCCTGGCCATCAAGATGATGAT
    CCGACTGACTCACAGGATACGACCATTCCCGATGTGGTGGTTGATCCCGATGATGGAAGCTACGGCGAAT
    ACCAGAGTTACTCGGAAAACGGCATGAATGCACCAGATGACTTGGTCCTATTCGATCTAGACGAGGACGA
    CGAGGACACTAAGCCAGTGCCTAATAGATCGACCAAGGGTGGACAACAGAAGAACAGTCAAAAGGGCCAG
    CATATAGAGGGCAGACAGACACAATCCAGGCCAATTCAAAATGTCCCAGGCCCTCACAGAACAATCCACC
    ACGCCAGTGCGCCACTCACGGACAATGACAGAAGAAATGAACCCTCCGGCTCAACCAGCCCTCGCATGCT
    GACACCAATTAACGAAGAGGCAGACCCACTGGACGATGCCGACGACGAGACGTCTAGCCTTCCGCCCTTG
    GAGTCAGATGATGAAGAGCAGGACAGGGACGGAACTTCCAACCGCACACCCACTGTCGCCCCACCGGCTC
    CCGTATACAGAGATCACTCTGAAAAGAAAGAACTCCCGCAAGACGAGCAACAAGATCAGGACCACACTCA
    AGAGGCCAGGAACCAGGACAGTGACAACACCCAGTCAGAACACTCTTTTGAGGAGATGTATCGCCACATT
    CTAAGATCACAGGGGCCATTTGATGCTGTTTTGTATTATCATATGATGAAGGATGAGCCTGTAGTTTTCA
    GTACCAGTGATGGCAAAGAGTACACGTATCCAGACTCCCTTGAAGAGGAATATCCACCATGGCTCACTGA
    AAAAGAGGCTATGAATGAAGAGAATAGATTTGTTACATTGGATGGTCAACAATTTTATTGGCCGGTGATG
    AATCACAAGAATAAATTCATGGCAATCCTGCAACATCATCAGTGAATGAGCATGGAACAATGGGATGATT
    CAACCGACAAATAGCTAACATTAAGTAGTCAAGGAACGAAAACAGGAAGAATTTTTGATGTCTAAGGTGT
    GAATTATTATCACAATAAAAGTGATTCTTATTTTTGAATTTAAAGCTAGCTTATTATTACTAGCCGTTTT
    TCAAAGTTCAATTTGAGTCTTAATGCAAATAGGCGTTAAGCCACAGTTATAGCCATAATTGTAACTCAAT
    ATTCTAACTAGCGATTTATCTAAATTAAATTACATTATGCTTTTATAACTTACCTACTAGCCTGCCCAAC
    ATTTACACGATCGTTTTATAATTAAGAAAAA
  • Protein Sequence : Show Sequence
    >gi|10314000|ref|NP_066243.1| NP [Zaire ebolavirus]
    MDSRPQKIWMAPSLTESDMDYHKILTAGLSVQQGIVRQRVIPVYQVNNLEEICQLIIQAFEAGVDFQESA
    DSFLLMLCLHHAYQGDYKLFLESGAVKYLEGHGFRFEVKKRDGVKRLEELLPAVSSGKNIKRTLAAMPEE
    ETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHAEQGLIQYPTAWQSVGHMMVIFRLMRTNFLI
    KFLLIHQGMHMVAGHDANDAVISNSVAQARFSGLLIVKTVLDHILQKTERGVRLHPLARTAKVKNEVNSF
    KAALSSLAKHGEYAPFARLLNLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEA
    EKQLQQYAESRELDHLGLDDQEKKILMNFHQKKNEISFQQTNAMVTLRKERLAKLTEAITAASLPKTSGH
    YDDDDDIPFPGPINDDDNPGHQDDDPTDSQDTTIPDVVVDPDDGSYGEYQSYSENGMNAPDDLVLFDLDE
    DDEDTKPVPNRSTKGGQQKNSQKGQHIEGRQTQSRPIQNVPGPHRTIHHASAPLTDNDRRNEPSGSTSPR
    MLTPINEEADPLDDADDETSSLPPLESDDEEQDRDGTSNRTPTVAPPAPVYRDHSEKKELPQDEQQDQDH
    TQEARNQDSDNTQSEHSFEEMYRHILRSQGPFDAVLYYHMMKDEPVVFSTSDGKEYTYPDSLEEEYPPWL
    TEKEAMNEENRFVTLDGQQFYWPVMNHKNKFMAILQHHQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
12. NP Marburgvirus - Ravn
  • Gene Name : NP Marburgvirus - Ravn
  • Sequence Strain (Species/Organism) : Ravn
  • VO ID : VO_0010933
  • NCBI Protein GI : 91177744
  • Locus Tag : ABE27068
  • Other Database IDs : CDD:147601
  • Taxonomy ID : 378809
  • Gene Strand (Orientation) : ?
  • Protein Name : nucleoprotein
  • Protein Length : 695
  • Protein Note : Ebola nucleoprotein; pfam05505
  • Protein Sequence : Show Sequence
    >gi|91177744|gb|ABE27068.1| nucleoprotein [Lake Victoria marburgvirus - Ravn]
    MDLHSLLELGTKPTAPHVRNKKVILFDTNHQVSICNQIIDAINSGIDLGDLLEGGLLTLCVEHYYNSDKD
    KFNTSPIAKYLRDAGYEFDVIKNPDATRFLEVIPNEPHYSPLILALKTLESTESQRGRIGLFLSFCSLFL
    PKLVVGDRASIEKALRQVTVHQEQGIVTYPNHWLTTGHMKVIFGILRSSFILKFVLIHQGVNLVTGHDAY
    DSIISNSVGQTRFSGLLIVKTVLEFILQKTDSGVALHPLVRTSKVKNEVASFKQALSNLARHGEYAPFAR
    VLNLSGINNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAAHDAEVKLQRRHEHQEIQAIAE
    DDEERKILEQFHLQKTEITHSQTLAVLSQKREKLARLAAEIENNIAEDQGFKQSQNQVSQSFLNDPTPVE
    VTVQARSINRPTALPPPVDNKIEHETEEDSSSSSSFVDLNDPFALLNEDEDTLENSVMAPSTTLREPKEV
    SEPLRQTQDLDISQKKQGNESTDPARKQFLRYQELPPVQEDDESEYTTDSQESDDQPGSDNEQGVDLPPP
    PLYAQEKRQDPIQHPAVSSQDPFGSIGDVDGDILEPIRSPSSPSAPQEDTRMGEAYELSPDFTSYEDNQQ
    NWPQRVVTKKGRTFLYPNDLLQTSPPESLITALVEEYQNPVSAKELQADWPDMSFDERRHVAMNL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Recombinant VEE Replicons expressing MBGV GP
13. PagA from Bacillus anthracis
  • Gene Name : PagA from Bacillus anthracis
  • Sequence Strain (Species/Organism) : Bacillus anthracis str. 'Ames Ancestor'
  • NCBI Gene ID : 2820165
  • NCBI Protein GI : 47566476
  • Locus Tag : GBAA_pXO1_0164
  • Genbank Accession : NC_007322.2
  • Protein Accession : YP_016495.2
  • Plasmid No : pXO1
  • Gene Starting Position : 143779
  • Gene Ending Position : 146073
  • Gene Strand (Orientation) : +
  • Protein Name : protective antigen
  • Protein pI : 6.09
  • Protein Weight : 85810.3
  • Protein Length : 764
  • Protein Note : similar to SP:P13423; identified by sequence similarity; putative
  • DNA Sequence : Show Sequence
    >GeneID|2820165 [Bacillus anthracis str. 'Ames Ancestor' ] 143779..146073
    tgtttggggccatcgttgcttatataaaaagtaaagaaacgaataaaaaggcatttgtgccagctttgtt
    ctttatggttgttgtaacaattctggagtgggtaccagcgcttcggattaatgatacagattggttatat
    ttaatggtgataccacttttattatgtaatgcatatcagttacttatattacatcgtttaattggaaaga
    cgagtaagtcggcctaattaagagcgtttttacgcaggatagttttatgtatgaaaatatcgggatgaaa
    aaagctccattacctgaatgaaaggtaatggagctttttatgtgtaaaaaattattgaacatctttactt
    ttcgtacttgtgttggaaataagttgtgatacggatatttgctcatagccgtcactctttaatttctgta
    gaagcagtggcaaagctttatttgtttgaagggcagaatcggatgcatgtaataagacgatatctccacc
    ttttaaattattagagacggtggaaacgatcttgtttacgccagggtttttccaatcgtttgagttatta
    ctccaatgaacgacagtgtatccgagtgattctgctattttaagtgttgctttgttaaagtctccactag
    gtggacgtaatagtttgatttgtttcacaccgagttttgtaaaaacatcttgtgctcgcagaagatctct
    tcttatttcatttgtctctagagaagtgtaggatgtgtaattataacccatactaccgatttcatgtcca
    tcttttatgatgcgttcaacaacatcagggtgtctttctgcccatgcagcagaaaggaagaaggttgcat
    tcttaatatctctttctttaagtgtatcaaggattggaattgcttttttgtctccccaactaatatcaaa
    cgtgaatgcaacttgttttttagaggtgtcgcctttgtaaataactttaggccctgtagcagttgaaaaa
    gcagactcgtgtgaatatgttttcaaaaagagtagccatgcggtaaataaggaaagtatcactattaagc
    taatgtgtttaaagtttcttttactcgtaataaaaaagaaaaacataatattacgcccctttgtccaatc
    cttttcagttacatatatgctgtaaatataaaaaagagaacaagggattaatatcgtaagtagtggatat
    aatggatggtaggattttgttaaatgaaaatcggcataatgtttattgctctgtaagaaatgattgaggt
    gatgatttgcttgggtttatgttaacgaaagaagagaaaaaagaaatggaatacatattgaagagagagt
    tagaagaacttttatttgattttgaagatgaacgtattcatgacgttgtaaaaaaggcgatggaagaaag
    atataaaatcattttttgtttgtttcgaagagtcgctaatgcagaggactgtattcgttacgtaagaaaa
    agaactttttattaaaaagtgttgacgttcatggttattatatgataaattaataaccgtcgctgatgcg
    gaaacgcagaaaacgacaaaaaagaaattgaaaaacttagttgacattgaaaaacgaagatgttaacata
    aggaagtcgcaaatgagcgaccaagtagttctttgaaaactgaacgaaacaaacaacgtgaaacgtcaat
    ttttattttagatgctagacaaactaactttattggagagtttgatcctggctcaggatgaacgctggcg
    gcgtgcctaatacatgcaagtcgagcgaatggattaagagcttgctcttatgaagttagcggcggacggg
    tgagtaacacgtgggtaacctgcccataagactgggataactccgggaaaccggggctaataccggataa
    cattttgaaccgcatggttcgaaattgaaaggtggcttcggctgccacttatggatggacccgcgtcgca
    ttagctagttggtgaggtaacggctcaccaaggcaatgatgcgtagccgacctgagagggtgatcggcca
    cactgggactgagacacggcccagactcctacgggaggcagcagtagggaatcttccgcaatggacgaaa
    gtctgacggagcaacgccgcgtgagtgatgaaggctttcgggtcgtaaaactctgttgttagggaagaac
    aagtgctagttgaataagctggcaccttgacggtacctaaccagaaagccacggctaactacgtgccagc
    agccgcggtaatacgtaggtggcaagcgttatccggaattattgggcgtaaagcg
  • Protein Sequence : Show Sequence
    >gi|47566476|ref|YP_016495.2| protective antigen [Bacillus anthracis str. 'Ames Ancestor' ]
    MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTG
    DLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKG
    RLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDND
    GIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEA
    RHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVS
    AGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTL
    ATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIAT
    YNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAF
    GFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHYDRN
    NIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQD
    GKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG
  • Related Vaccine(s): Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
14. SGP
  • Gene Name : SGP
  • Sequence Strain (Species/Organism) : Sudan ebolavirus strain Boniface
  • NCBI Protein GI : 1041225
  • Protein Accession : AAB37096.1
  • Taxonomy ID : 186540
  • Gene Strand (Orientation) : ?
  • Protein Name : virion spike glycoprotein precursor
  • Protein Length : 2362
  • Protein Note : subtype: Sudan
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Marburg virus recombinant vector vaccine CAdVax-Panfilo
15. VP24
  • Gene Name : VP24
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus
  • NCBI Gene ID : 920943
  • NCBI Protein GI : 13489281
  • Locus Tag : MARVgp6
  • Genbank Accession : NC_001608.2
  • Protein Accession : NP_042030.1
  • Taxonomy ID : 11269
  • Gene Starting Position : 10205
  • Gene Ending Position : 10966
  • Gene Strand (Orientation) : +
  • Protein Name : VP24 protein
  • Protein pI : 8.27
  • Protein Weight : 28621.3
  • Protein Length : 253
  • DNA Sequence : Show Sequence
    >GeneID|920943 [Lake Victoria marburgvirus ] 10205..10966
    atggcagaattatcaacgcgttacaacttgcctgcaaatgttacggaaaaaagcataaatcttgacctta
    attccacagcacgatggataaaagaacccagtgttgggggctggacagtgaagtggggaaactttgtttt
    ccacataccaaatactgggatggcattgttgcatcatttaaagtctaacttcgttgttccagagtggcaa
    caaacaaggaatctattctcccacctctttaaaaacccaaagtcaacaattatagaaccgttcttggctt
    tgaggatcttgcttggagttgctttgaaggatcaagaattacagcaatcattaattcctggatttagatc
    tattgttcatatgctttcagaatggttgctcctagaggtaacgtcggcaatccatattagccccaatctg
    ttgggaatctatttgacctcagacatgtttaagattctgatggcaggtgtgaaaaatttctttaataaga
    tgttcactcttcatgttgtaaatgaccacggaaaacccagcagtattgaaataaagttaactggacaaca
    gatcattatcactcgtgttaatatggggtttctagtggaagtcaggaggattgatattgaaccttgttgt
    ggtgagacagtcctctcagaatcagttgtttttgggctagtggctgaggcagttctaagagaacacagtc
    aaatggagaagggccaacccctcgatctgacacaatacatgaacagcaaaattgctatataa
  • Protein Sequence : Show Sequence
    >gi|13489281|ref|NP_042030.1| VP24 protein [Lake Victoria marburgvirus ]
    MAELSTRYNLPANVTEKSINLDLNSTARWIKEPSVGGWTVKWGNFVFHIPNTGMALLHHLKSNFVVPEWQ
    QTRNLFSHLFKNPKSTIIEPFLALRILLGVALKDQELQQSLIPGFRSIVHMLSEWLLLEVTSAIHISPNL
    LGIYLTSDMFKILMAGVKNFFNKMFTLHVVNDHGKPSSIEIKLTGQQIIITRVNMGFLVEVRRIDIEPCC
    GETVLSESVVFGLVAEAVLREHSQMEKGQPLDLTQYMNSKIAI
  • Related Vaccine(s): Marburg virus recombinant vector vaccine MBGV GP , Recombinant VEE Replicons expressing MBGV GP
16. VP30
  • Gene Name : VP30
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus
  • NCBI Gene ID : 920942
  • NCBI Protein GI : 13489280
  • Locus Tag : MARVgp5
  • Genbank Accession : NC_001608.2
  • Protein Accession : NP_042029.1
  • Taxonomy ID : 11269
  • Gene Starting Position : 8867
  • Gene Ending Position : 9712
  • Gene Strand (Orientation) : +
  • Protein Name : VP30 protein
  • Protein pI : 9.78
  • Protein Weight : 31640.5
  • Protein Length : 281
  • DNA Sequence : Show Sequence
    >GeneID|920942 [Lake Victoria marburgvirus ] 8867..9712
    atgcaacaaccccgtggaaggagtcgaactcgcaaccaccaaaccgcatcatctatatatcatgaaactc
    agttgccctccaaacctcactacaccaatcatcatccacgtgcaagatcgatgagctcaacccgcagtag
    tgcagaaagcagtcccaccaatcatattccccgtgctcgaccacccccaacattcaacttatcgaaaccc
    cctcctcctccaaaagacatgtgtaggaacatgaaaattggattgccgtgcactgatcccacttgtaata
    gagatcatgaccttgataatctaacaaatcgtgaacttttgctattgatggcccgaaaaatgctccccaa
    tacagacaagacttttagaagtctgcaggattgtgggtcaccgtctctttctaaagggctctcaaaagat
    aaacaggagcaaacgaaagatgtgttgaccttggaaaatctaggacacattctgaactacctccacagat
    cagatattgggaaattggatgagacatcactccgtgcagcattaagtttgacgtgcgctggaattcgaaa
    gacgaatagatccttgatcaacaccatgaccgaattacacattaaccatgaaaatctcccgcaagaccaa
    aacggtgttatcaaacagacatatacaggtattcaccttgacaaaggaggtcaattcgaagccgccttat
    ggcaaggttgggataagagatcgatatctttattcgtacaagcagctttatatgtaatgaacaatatccc
    ttgtgaatcatcaaccagtgtgcaagcctcatacgatcattttattcttcctcaaagtcaaagtaaagga
    caatga
  • Protein Sequence : Show Sequence
    >gi|13489280|ref|NP_042029.1| VP30 protein [Lake Victoria marburgvirus ]
    MQQPRGRSRTRNHQTASSIYHETQLPSKPHYTNHHPRARSMSSTRSSAESSPTNHIPRARPPPTFNLSKP
    PPPPKDMCRNMKIGLPCTDPTCNRDHDLDNLTNRELLLLMARKMLPNTDKTFRSLQDCGSPSLSKGLSKD
    KQEQTKDVLTLENLGHILNYLHRSDIGKLDETSLRAALSLTCAGIRKTNRSLINTMTELHINHENLPQDQ
    NGVIKQTYTGIHLDKGGQFEAALWQGWDKRSISLFVQAALYVMNNIPCESSTSVQASYDHFILPQSQSKG
    Q
  • Related Vaccine(s): Marburg virus recombinant vector vaccine MBGV GP , Recombinant VEE Replicons expressing MBGV GP
17. VP35
  • Gene Name : VP35
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus
  • VO ID : VO_0010929
  • NCBI Gene ID : 920948
  • NCBI Protein GI : 13489277
  • Locus Tag : MARVgp2
  • Genbank Accession : NC_001608.2
  • Protein Accession : NP_042026.1
  • Taxonomy ID : 11269
  • Gene Starting Position : 2944
  • Gene Ending Position : 3933
  • Gene Strand (Orientation) : +
  • Protein Name : VP35 protein
  • Protein pI : 8.94
  • Protein Weight : 36149.4
  • Protein Length : 329
  • DNA Sequence : Show Sequence
    >GeneID|920948 [Lake Victoria marburgvirus ] 2944..3933
    atgtgggactcatcatatatgcaacaagtcagtgaggggttgatgactggaaaagttcccatagatcaag
    tgtttggtgccaatccctcagagaagttacacaagagaaggaaaccaaaaggcacagttggactacaatg
    cagcccttgtctaatgtcaaaggcgacaagcactgatgatattgtttgggaccaactgatcgtgaagaaa
    acactagctgatctacttataccgataaataggcagatatcggacattcaaagcactctaaacgaagtaa
    caacaagagtccatgaaattgagcggcaattacatgagataaccccagtgttaaaaatgggaaggacact
    ggaagcaatttccaaggggatgtcagaaatgttagccaaatacgaccacctcgtaatttcaactggaaga
    accactgcaccagctgctgcctttgatgcttacttaaatgagcatggtgtccctcccccccaacctgcga
    ttttcaaagatcttggggttgctcaacaagcttgtagtaaggggaccatggttaaaaatgaaacaacaga
    tgcagccgacaagatgtcgaaagttcttgaactcagtgaggagacgttctccaagccaaatctttcagct
    aaggatttagcccttttgttgtttacccatctacccggcaacaacactccattccatatcctagctcaag
    tcctttcaaaaattgcttacaagtcaggaaagtccggagcatttttggatgcatttcaccagattctaag
    tgaaggagagaatgctcaggcagcattgactcgactaagcagaacatttgatgctttcctcggagtagtt
    cctccagtgataagagtcaaaaacttccaaacagtccctcgcccatgtcaaaaaagtcttcgggctgttc
    ctcccaacccaacaattgacaaaggatgggtctgtgtttattcatctgagcaaggtgagacacgggccct
    gaaaatctaa
  • Protein Sequence : Show Sequence
    >gi|13489277|ref|NP_042026.1| VP35 protein [Lake Victoria marburgvirus ]
    MWDSSYMQQVSEGLMTGKVPIDQVFGANPSEKLHKRRKPKGTVGLQCSPCLMSKATSTDDIVWDQLIVKK
    TLADLLIPINRQISDIQSTLNEVTTRVHEIERQLHEITPVLKMGRTLEAISKGMSEMLAKYDHLVISTGR
    TTAPAAAFDAYLNEHGVPPPQPAIFKDLGVAQQACSKGTMVKNETTDAADKMSKVLELSEETFSKPNLSA
    KDLALLLFTHLPGNNTPFHILAQVLSKIAYKSGKSGAFLDAFHQILSEGENAQAALTRLSRTFDAFLGVV
    PPVIRVKNFQTVPRPCQKSLRAVPPNPTIDKGWVCVYSSEQGETRALKI
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Guinea pigs were vaccinated with recombinant VEE replicons (packaged into VEE-like particles), inoculated with MBGV, and evaluated for viremia and survival after challenge with typical MGBV disease. Results indicated that VP35 afforded incomplete protection (Hevey et al., 1998).
  • Related Vaccine(s): Marburg virus recombinant vector vaccine MBGV GP , Recombinant VEE Replicons expressing MBGV GP
18. VP40
  • Gene Name : VP40
  • Sequence Strain (Species/Organism) : Lake Victoria marburgvirus
  • NCBI Gene ID : 920947
  • NCBI Protein GI : 13489278
  • Locus Tag : MARVgp3
  • Genbank Accession : NC_001608.2
  • Protein Accession : NP_042027.1
  • Taxonomy ID : 11269
  • Gene Starting Position : 4567
  • Gene Ending Position : 5478
  • Gene Strand (Orientation) : +
  • Protein Name : VP40 protein
  • Protein pI : 9.66
  • Protein Weight : 33734.4
  • Protein Length : 303
  • DNA Sequence : Show Sequence
    >GeneID|920947 [Lake Victoria marburgvirus ] 4567..5478
    atggccagttccagcaattacaacacatacatgcaatacttgaacccccctccttatgctgatcacggtg
    caaaccagttgatcccggcggatcagctatcaaatcagcagggtataactccaaattatgtgggtgactt
    aaacctagatgatcagttcaaagggaatgtctgccatgctttcactttagaggcaataattgacatatct
    gcgtataatgaaccaacagtcaaaggtgttccagcatggctgcctctcgggattatgagcaattttgaat
    atcctttagctcatactgtggctgcgttgctcacaggcagctatacaatcacccaatttactcataatgg
    gcaaaaattcgtccgtgtaaatcgactcggtacaggaatcccagcacacccactcagaatgttgcgtgaa
    ggaaatcaagcttttattcagaatatggtgatccccagaaatttttccactaatcaattcacctacaatc
    tcactaacttagtattgagtgtgcaaaagcttcctgatgatgcctggcgcccatccaaggacaaattaat
    tgggaacaccatgcatcccgcagtctccatacacccgaatttgccacccattgttctaccaacagtcaag
    aagcaggcttatcgtcagcataaaaatcccaacaatggaccactgctggccatatctggcatccttcacc
    aactgagggtcgagaaagtcccagagaagacaagcctgtttaggatttcacttcctgccgatatgttctc
    agtaaaagaaggtatgatgaagaaaaggggagaaaattccccggtggtttattttcaagcacctgagaac
    ttccctttgaatggcttcaacaacagacaagttgtactagcgtatgcgaatccaacgctcagtgccgttt
    ga
  • Protein Sequence : Show Sequence
    >gi|13489278|ref|NP_042027.1| VP40 protein [Lake Victoria marburgvirus ]
    MASSSNYNTYMQYLNPPPYADHGANQLIPADQLSNQQGITPNYVGDLNLDDQFKGNVCHAFTLEAIIDIS
    AYNEPTVKGVPAWLPLGIMSNFEYPLAHTVAALLTGSYTITQFTHNGQKFVRVNRLGTGIPAHPLRMLRE
    GNQAFIQNMVIPRNFSTNQFTYNLTNLVLSVQKLPDDAWRPSKDKLIGNTMHPAVSIHPNLPPIVLPTVK
    KQAYRQHKNPNNGPLLAISGILHQLRVEKVPEKTSLFRISLPADMFSVKEGMMKKRGENSPVVYFQAPEN
    FPLNGFNNRQVVLAYANPTLSAV
  • Related Vaccine(s): Heterologous MARV Protein VLP , Marburg virus recombinant vector vaccine MBGV GP , Marburg virus-like particles , Recombinant VEE Replicons expressing MBGV GP
III. Vaccine Information
1. Adenovirus vectors expressing Marburg virus glycoprotein
a. Vaccine Ontology ID:
VO_0004118
b. Type:
Recombinant vector vaccine
c. Antigen
Glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
d. Gene Engineering of GP from Marburg virus Ci67
  • Type: Recombinant protein preparation
  • Description: This Ci67 GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
e. Gene Engineering of GP from Marburg virus Ravn
  • Type: Recombinant protein preparation
  • Description: This Ravn GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
f. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant protein preparation
  • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
g. Preparation
The Ci67 GP (Genbank accession number AF005735; Protein ID AAC40460.1; a.a. 1–681), Ravn GP (Genbank accession number AF005734; Protein ID AAC40459.1; a.a. 1–681), and Musoke GP (Genbank accession number DQ217792; Protein ID ABA87127; a.a. 1–681) genes were amplified by PCR. Each MARV antigen was subcloned into the pLAd and pRAd shuttle vectors to create a series of MARV adenovirus vaccines targeted against the Ci67, Ravn, and Musoke strains of MARV. All cAdVax vector genomes were based on a modified Ad5sub360 vector backbone, which contains deletions in E1, E3 and almost all E4 ORFs with the exception of ORF6 (Wang et al., 2006).
h. Virulence
Although Ad vectors have a high affinity for the liver and may potentially cause inflammation in the liver, there is not pathology indicative of inflammation or cytotoxicity as a result of vaccination in mice (Wang et al., 2006).
i. Mouse Response
  • Host Strain: C57BL/6 mice
  • Vaccination Protocol: Four groups of 28 C57BL/6 mice were immunized intra-peritoneally (i.p.) at weeks 0, 4 and 8 with 1 × 108 pfu of either cAdVaxM(ci), cAdVaxM(ra), cAdVaxM(mu), or HC4 control vector prepared in 100 μl PBS/10% glycerol. HC4, an unrelated adenovirus-based Hepatitis C vaccine, served as a negative control vaccine. Four mice per group were sacrificed at weeks 2, 4, 6, 8, 10, 12, and 24 (Wang et al., 2006).
  • Persistence: The persistence of these three vaccine candidates in mice was not reported.
  • Immune Response: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) induced efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus (Wang et al., 2006).
  • Side Effects: Three 1 × 108 pfu doses of vaccine vector did not lead to any detectable toxicity in liver or spleen, so it appears to be safe (Wang et al., 2006).
  • Challenge Protocol: No challenge experiment was conducted.
2. CAdVa-Filoviruses (EbMarburg viruses)
a. Vaccine Ontology ID:
VO_0004645
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant vector construction
  • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
f. Gene Engineering of GP from Marburg virus Ravn
  • Type: Recombinant vector construction
  • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
g. Gene Engineering of GP from Marburg virus Ci67
  • Type: Recombinant vector construction
  • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
h. Preparation
Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
i. Immunization Route
Intramuscular injection (i.m.)
j. Mouse Response
  • Vaccination Protocol: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) (Wang et al., 2006).
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Vaccination led to efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also shown to be cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus. Additionally, three 1 x 10(8)pfu doses of vaccine vector were demonstrated to be safe in mice, as this did not lead to any detectable toxicity in liver or spleen (Wang et al., 2006).
3. cAdVaxM(fus)
a. Vaccine Ontology ID:
VO_0004646
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant vector construction
  • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
f. Gene Engineering of GP from Marburg virus Ravn
  • Type: Recombinant vector construction
  • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
g. Gene Engineering of GP from Marburg virus Ci67
  • Type: Recombinant vector construction
  • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
h. Preparation
Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
i. Immunization Route
Intramuscular injection (i.m.)
j. Mouse Response
  • Vaccination Protocol: Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines) (Wang et al., 2006).
  • Vaccine Immune Response Type: VO_0003057
  • Description: Vaccination led to efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also shown to be cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus. Additionally, three 1 x 10(8)pfu doses of vaccine vector were demonstrated to be safe in mice, as this did not lead to any detectable toxicity in liver or spleen (Wang et al., 2006).
4. Heterologous MARV Protein VLP
a. Vaccine Ontology ID:
VO_0004137
b. Type:
Subunit vaccine
c. Antigen
MARV VP40 and GP were used (Swenson et al., 2005).
d. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant protein preparation
  • Description: MBGV gene clone pGem-GP was provided by Heinz Feldmann and Anthony Sanchez (Centers for Disease Control and Prevention, Atlanta, GA). The MBGV GP gene from pGem-GP was excised with SalI and subcloned into the SalI site of a shuttle vector. A clone with the MBGV GP gene in the correct orientation was excised with ApaI and NotI, and this fragment was cloned into the ApaI and NotI sites of a VEE replicon plasmid (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
e. Gene Engineering of VP40
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP40. VP40 seems to serve as a matrix protein, affecting interactions between the nucleoprotein complex and lipid membrane. It is also the most abundant part of the virion (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
f. Adjuvant: Ribi vaccine adjuvant
g. Preparation
Expression plasmids were made through the use of MARV-Musoke strain. To produce the actual viral preparations, MARV-infected cell supernatents were clarified at 1500×g and then pelleted at 9500×g for 4 h in a Sorvall GSA rotor (Swenson et al., 2005).
h. Virulence
GP vaccination formed sufficient protection against homologous filovirus challenge, yet heterologous wild-type VLPs without GP failed to protect. Our data indicate that vaccination with GP was required and sufficient to form an immune response as heterologous wild-type VLPs or hybrid VLPs that did not contain the homologous GP failed. Vaccination with a mixture of EBOV and MARV VLPs was successful in forming an immune response (Swenson et al., 2005).

i. Guinea pig Response
  • Host Strain: Strain 13
  • Vaccination Protocol: Strain 13 guinea pigs were vaccinated once with mVLPs, eVLPs, or an equal mixture of eVLPs and mVLPs in RIBI adjuvant, and the serum antibody levels against MARV and EBOV were measured (via ELISA) prior to challenge (Swenson et al., 2005).
    Control guinea pigs were vaccinated with RIBI adjuvant alone. Serum samples from the guinea pigs were
    obtained immediately before (PRE) or 28 days post-challenge (POST).Guinea pigs were vaccinated
  • Persistence: Not noted.
  • Immune Response: Animals vaccinated with the wild-type eVLP or e/m-VLPs did not have high serum antibody titers against MARV, but did have them against EBOV. Injection with mVLP and m/e-VLP vaccination resulted in high titers against MARV but not against EBOV. The vaccination containing EBOV GPin the form of eVLPor e/m-VLP resulted in antibodies against EBOV but not MARV. Finally, animals vaccinated with mVLP orm/e-VLP did not develop significant antibody titers against EBOV or MARV (Swenson et al., 2005).
  • Side Effects: None noted.
  • Challenge Protocol: Guinea pigs were challenged 28 days after a single vaccination with 1000 pfu of guinea pig-adapted MARV or EBOV (Swenson et al., 2005).
  • Efficacy: Guinea pigs challenged wuth VLPs containing homologous GP were protected from a lethal filovirus, and a eVLP or e/m-VLP vaccination yielded protection against EBOV infection. Vaccines containing heterologous proteins or homologous VP40 did not protect against lethal challenge (Swenson et al., 2005).
5. Irradiated MBGV antigen
a. Vaccine Ontology ID:
VO_0004127
b. Type:
Inactivated or "killed" vaccine
c. Antigen
Whole Marburg virus (MBGV) antigens (Hevey et al., 1997).
d. Guinea pig Response
  • Host Strain: Strain 13
  • Vaccination Protocol: Animals were immunized with irradiated MBGV (strains Musoke and Ravn)(Hevey et al., 1997).
  • Persistence: None noted.
  • Immune Response: Not noted for irradiated MBGV specifically.
  • Side Effects: None noted.
  • Challenge Protocol: All animals challenged with strains Musoke and Ravn survived without regard to challenge virus (Hevey et al., 1997).
  • Efficacy: Gradient-purified, irradiated virus was able to completely protect strain 13 guinea pigs from challenge with either MBGV (strain Musoke) or
    indicated that the product immunoprecipitated from GP- MBGV (strain Ravn)(Hevey et al., 1997).
6. Marburg virus DNA prime/boost vaccine DNA/rAd5-GP encoding GP from strain Angola
a. Vaccine Ontology ID:
VO_0004389
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaque
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: DNA vaccine construction
  • Description: Vector rAd type 5 (rAd5) expressed GP of MARV (Geisbert et al., 2010).
  • Detailed Gene Information: Click here.
f. Vector:
CMV/R and rAd type 5 (rAd5) (Geisbert et al., 2010)
g. Immunization Route
Intramuscular injection (i.m.)
h. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The vaccine induced humoral responses , as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP. The highest antibody titers were achieved with a heterologous prime-boost vaccine. rAd5-GP boosted titers in DNA-primed animals more than 2 orders of magnitude to a final prechallenge GP ELISA IgG titer of 1:237,167 (Geisbert et al., 2010).
  • Efficacy: Heterologous prime-boost with DNA/rAd vectors generated protective immunity in all subjects after challenge with a lethal dose of MARV Angola (Geisbert et al., 2010).
7. Marburg virus DNA vaccine DNA-GP encoding GP
a. Vaccine Ontology ID:
VO_0004390
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaque
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
f. Vector:
CMV/R (Geisbert et al., 2010)
g. Immunization Route
Intramuscular injection (i.m.)
h. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The DNA/DNA vaccine induced humoral responses comparable to those induced by a single inoculation with rAd5-GP, as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP (Geisbert et al., 2010).
  • Efficacy: The DNA-GP-only vaccine prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola (Geisbert et al., 2010).
8. Marburg virus DNA vaccine MARV GP encoding GP
a. Vaccine Ontology ID:
VO_0004387
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse, rabbit, guinea pig
e. Gene Engineering of GP from Marburg virus Ravn
  • Type: DNA vaccine construction
  • Description: Vector pWRG7077 expressed MARV Musoke GP in challenge study with macaques (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click here.
f. Vector:
pWRG7077 (Riemenschneider et al., 2003)
g. Immunization Route
Intramuscular injection (i.m.)
h. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: All of the MARV GP DNA-vaccinated guinea pigs developed antibodies to MARV (Riemenschneider et al., 2003).
  • Efficacy: In both studies (two different strains - Musoke and Ravn), two of three GP DNA-vaccinated monkeys were aviremic on the days assayed, and survived challenge, while one monkey in each study developed viremia levels similar to those of control monkeys and died. These results indicate that DNA vaccination alone is able to offer immunity to nonhuman primates, but suggest that the protective effect is near the threshold of vaccine efficacy (Riemenschneider et al., 2003).
9. Marburg virus glycoprotein expressed by baculovirus recombinants
a. Vaccine Ontology ID:
VO_0004128
b. Type:
Live, attenuated vaccine
c. Antigen
The full-length and truncated GP were expressed by baculovirus recombinants (Hevey et al., 1997). Both antigens were abundantly glycosylated with both N- and O-linked glycans.
d. Gene Engineering of NP from Marburg virus Musoke
  • Type: Recombinant protein preparation
  • Description: This Musoke NP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant protein preparation
  • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
f. Preparation
MBGV glycoprotein (GP) was expressed in Baculovirus recombinants either as a slightly truncated product secreted into medium or a complete, cell-associated molecule(Hevey et al., 1997).
g. Virulence
Irradiated MBGV antigen was protective against two MBGV strains (Musoke and Ravn). The recombinant truncated glycoprotein did elicit protection against challenge with the MBGV isolate from which it was taken(Hevey et al., 1997).
h. Guinea pig Response
  • Host Strain: Strain 13 and Hartley
  • Vaccination Protocol: Groups of animals were challenged with Ravn and Musoke strains, and ELISA titers were use to measure response 28 days after challenge (Hevey et al., 1997).
  • Immune Response: Irradiated, gradient-purified virus completely protected Strain 13 from both Ravn and Musoke MBGV strains (Hevey et al., 1997).
  • Challenge Protocol: Guinea pigs (Hartley and Strain 13) were divided into groups and injected with irradiated GP or recombinant GP. ELISA titers measureing response were taken 2 days before challenge and 28 days after for comparison (Hevey et al., 1997).
  • Description: Animals that recieved the MBGV antigen (strainRavn) had a lower survival rate than those challenged with the Musoke strain(Hevey et al., 1997).
10. Marburg Virus Nucleoprotein Vaccine
a. Vaccine Ontology ID:
VO_0011394
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Gene Engineering of NP from Lake Victoria marburgvirus
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
An RNA replicon, based upon Venezuelan equine encephalitis (VEE) virus, was used as a vaccine vector (Hevey et al., 1998).
f. Immunization Route
Subcutaneous injection
g. Macaque Response
  • Host Strain: Macaca fascicularis
  • Vaccination Protocol: Twelve cynomolgus macaques (Macaca fascicularis), 11 females and 1 male, ranging from 2.8 to 4.5 kg, were inoculated subcutaneously with 107 FFU of VRP in a total volume of 0.5 ml at one site. Monkeys were anesthetized with ketamine, bled, and inoculated (as described for the first vaccine dose) 28 days after the primary injection, and again 28 days after the second (Hevey et al., 1998).
  • Challenge Protocol: Animals were challenged 14 days after 3rd vaccine dose with 103.9 PFU MBGV
    subcutaneously (Hevey et al., 1998).
  • Efficacy: MBGV NP afforded incomplete (partial) protection, sufficient to prevent death but not disease in two of three macaques (Hevey et al., 1998).
11. Marburg virus recombinant vector vaccine CAdVax-Panfilo
a. Vaccine Ontology ID:
VO_0004388
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaque
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant vector construction
  • Description: This DNA vaccine expressed MARV Musoke GP (Swenson et al., 2008).
  • Detailed Gene Information: Click here.
f. Gene Engineering of NP from Marburg virus Musoke
  • Type: Recombinant vector construction
  • Description: This DNA vaccine expressed MARV Musoke NP (Swenson et al., 2008).
  • Detailed Gene Information: Click here.
g. Gene Engineering of GP from Marburg virus Ci67
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of GP from Marburg virus Ravn
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
i. Gene Engineering of NP
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
j. Gene Engineering of GP
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
k. Gene Engineering of SGP
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
l. Vector:
CAdVax (Swenson et al., 2008)
m. Immunization Route
Intramuscular injection (i.m.)
n. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: All vaccinated animals from groups 1(challenged with 1,000 PFU MARV Musoke) and 2 (challenged with the same dose of ZEBOV) mounted strong antibody titers against all five filoviruses with similar kinetics (Swenson et al., 2005).
  • Efficacy: Vaccination of NHP with CAdVax-Panfilo was 100% protective against challenge with multiple filovirus species, including ZEBOV, SEBOV, MARV Musoke, and MARV Ci67 (Swenson et al., 2005).
12. Marburg virus recombinant vector vaccine MBGV GP
a. Vaccine Ontology ID:
VO_0004391
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Guinea pig, macaques
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant vector construction
  • Description: Vector Venezuelan equine encephalitis (VEE) virus expressed the gene for MBGV GP (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
f. Vector:
Venezuelan equine encephalitis (VEE) virus (Hevey et al., 1998)
g. Immunization Route
Intramuscular injection (i.m.)
h. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Three monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that expressed GP or NP, remained aviremic and were completely protected from disease (Hevey et al., 1998).
13. Marburg virus recombinant vector vaccine MBGV GP/MBGV NP
a. Vaccine Ontology ID:
VO_0004566
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Guinea pig, macaques
e. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of NP from Marburg virus Musoke
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
g. Vector:
Venezuelan equine encephalitis (VEE) virus (Hevey et al., 1998)
h. Immunization Route
subcutaneous injection
i. Macaque Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Three monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that expressed GP or NP, remained aviremic and were completely protected from disease (Hevey et al., 1998).
14. Marburg virus-like particles
a. Vaccine Ontology ID:
VO_0004117
b. Type:
Subunit vaccine
c. Antigen
MARV or EBOV VP40 and GP (Warfield et al., 2004).
d. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant protein preparation
  • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
e. Gene Engineering of VP40
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP40. VP40 seems to serve as a matrix protein, affecting interactions between the nucleoprotein complex and lipid membrane. It is also the most abundant part of the virion (Hevey et al., 1998).

  • Detailed Gene Information: Click here.
f. Adjuvant: Ribi vaccine adjuvant
g. Preparation
To generate mVLPs, 293T cells were co-transfected with pWRG 7077 vectors encoding for MARV VP40 and GP using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). To purify the VLPs, the cell supernatants were cleared from cellular debris and subsequently pelleted at 9500×g for 4 h. The crude VLP preparations were then separated on a 20â��60% continuous sucrose gradient centrifuged. The VLPs were concentrated by a second centrifugation and resuspended in endotoxin-free phosphate-buffered saline (PBS) (Warfield et al., 2004).
h. Virulence
Guinea pigs that were vaccinated with inactivated MARV or mVLPs developed MARV-specific antibody titers(Warfield et al., 2004).
i. Guinea pig Response
  • Host Strain: Strain 13
  • Vaccination Protocol: Guinea pigs were vaccinated intramuscularly with 50 μg of mVLPs, eVLPs, or iMARV with 200 μl of RIBI monophosphoryl lipid+synthetic trehalose dicorynomycolate+cell wall skeleton emulsion diluted in endotoxin-free PBS (Warfield et al., 2004).
  • Persistence: None noted.
  • Immune Response: Both inactivated MARV and mVLP induced maximal humoral responses to MARV after only two vaccinations (Warfield et al., 2004) .
  • Side Effects: Not noted.
  • Challenge Protocol: Thirty days after the third vaccination, the guinea pigs were challenged subcutaneously with 1000 plaque-forming units (pfu) or 2000 LD50 of guinea pig-adapted MARV diluted in PBS [18](Warfield et al., 2004).
  • Efficacy: Strong filovirus-specific antibody responses correlate with vaccine protective efficacy in guinea pigs(Warfield et al., 2004).
15. Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
a. Vaccine Ontology ID:
VO_0004130
b. Type:
DNA vaccine
c. Antigen
Multiple antigens from B. anthracis, Ebola virus, Marburg virus, and VEE virus were used. Specifically, this DNA vaccine includes Protective Antigen (PA) from B. anthracis, Glycoprotein (GP) and Nucleoprotein (NP) from Ebloa virus, Glycoprotein (GP) from Marburg virus strain Ravn, and 26S from VEE virus (Riemenschneider et al., 2003).
d. Gene Engineering of PagA from Bacillus anthracis
  • Type: Recombinant protein preparation
  • Description: A DNA vaccine for the anthrax was made by PCR-amplifying the PA gene (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click here.
e. Gene Engineering of NP from Zaire ebolavirus
  • Type: Recombinant protein preparation
  • Description: Ebola NP genes were cloned and the vaccine was produced without additional signal sequence with the use of plasmid pWRG7077 (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click here.
f. Gene Engineering of GP from Zaire ebolavirus
  • Type: Recombinant protein preparation
  • Description: Ebola NP genes were cloned and the vaccine was produced without additional signal sequence with the use of plasmid pWRG7077 (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click here.
g. Gene Engineering of GP from Marburg virus Ravn
  • Type: Recombinant protein preparation
  • Description: This Ravn GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click here.
h. Gene Engineering of 26S mRNA from VEEV
  • Type: Recombinant protein preparation
  • Description: The vaccine for 26S mRNA was produced without additional signal sequence with the use of plasmid pWRG7077 (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click here.
i. Vector:
pWRG7079 (Riemenschneider et al., 2003)
j. Preparation
The necessary genes were inserted into expression plasmids following a cytomegalovirus immediate early promotor. MARV was procured through experiementally infected monkeys, then passed three times (Ravn) or one time(Musoke) in Vero cells. Inbred Strain 13 and outbred Hartley guinea pigs were injected subcutaneously with the vaccine. Responses were measured by IgG antibody ELISA with the use of cobalt-irradiated purified MARV in both strains. A study also included non-human primates, which underwent serum tests for viremia determination and blood chemistry(Riemenschneider et al., 2003).
k. Guinea pig Response
  • Host Strain: Strain 13 and Hartley
  • Vaccination Protocol: Gun-vaccinated guinea pigs were gene gun-vaccinated three (Musoke) or four (Ravn) times at 4-week intervals with approximately 2.5 μg of the MARV GP DNA (Riemenschneider et al., 2003).
  • Persistence: Not noted.
  • Immune Response: All of the MARV GP DNA-vaccinated guinea pigs developed antibodies to MARV(Riemenschneider et al., 2003).
  • Side Effects: Not noted.
  • Challenge Protocol: The challenge was a subcutaneous injection of 1000 plaque forming units (pfu) of homologous virus 4 weeks after the final vaccination for each guinea pig (Riemenschneider et al., 2003).
  • Efficacy: Guinea pigs vaccinated with control DNA were viremic at day 7 post-challenge, as measured by plaque assay, and were infected by day 9. All guinea pigs vaccinated with the GP DNA vaccines were aviremic at day 7 and appreared healthy throughout the observation period(Riemenschneider et al., 2003).
16. Recombinant VEE Replicons expressing MBGV GP
a. Vaccine Ontology ID:
VO_0004125
b. Type:
Recombinant vector vaccine
c. Antigen
Marburg virus (MBGV) GP (Hevey et al., 1998). An RNA replicon from Venezuelan equine encephalitis (VEE) virus was used as a vaccine vector. The VEE structural genes were replaced by genes for MBGV GP, nucleoprotein (NP), VP30, VP35, VP40, or VP24 (Hevey et al., 1998).
d. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant vector construction
  • Description: MBGV gene clone pGem-GP was provided by Heinz Feldmann and Anthony Sanchez (Centers for Disease Control and Prevention, Atlanta, GA). The MBGV GP gene from pGem-GP was excised with SalI and subcloned into the SalI site of a shuttle vector. A clone with the MBGV GP gene in the correct orientation was excised with ApaI and NotI, and this fragment was cloned into the ApaI and NotI sites of a VEE replicon plasmid (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
e. Gene Engineering of NP Marburgvirus - Ravn
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of VP30
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP30. Function has yet to be determined; VP30 is found on the VP40 virion (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
g. Gene Engineering of VP35
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP35. Function has yet to be determined; VP35 is found on the VP40 virion (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
h. Gene Engineering of VP40
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP40. VP40 seems to serve as a matrix protein, affecting interactions between the nucleoprotein complex and lipid membrane. It is also the most abundant part of the virion (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
i. Gene Engineering of VP24
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP24. Function has yet to be determined; VP24 is found on the VP40 virion (Hevey et al., 1998).
  • Detailed Gene Information: Click here.
j. Preparation
Guinea pigs were inoculated with packaged recombinant VEE replicons expressing individual MBGV proteins and later injected with 103.3 LD50 guinea pig-adapted MBGV subcutaneously(Hevey et al., 1998).
k. Virulence
MBGV NP protected all vaccinated guinea pigs from both death and viremia, while MBGV VP35 vaccination resulted in a majority of the animals surviving. Four of the five survivors were viremic 7 days after infection(Hevey et al., 1998).
l. Description
Results indicated that VP35 afforded incomplete protection while either GP or NP were protective antigens(Hevey et al., 1998).
m. Monkey Response
  • Host Strain: cynomolgus
  • Vaccination Protocol: Several groups of macaques were tested: a group received VRPs that expressed MBGV NP; a group received VRPs that expressed MBGV GP; a group received a mixture of MBGV GP and MBGV NP VRPs; and a group received VRPs that expressed a control antigen (influenza HA)Anti-MBGV ELISA antibody titers were monitored throughout the experiment(Hevey et al., 1998).
  • Persistence: Not noted.
  • Immune Response: Animals inoculated with replicons that expressed MBGV proteins demonstrated prechallenge ELISA titers to purified MBGV antigen. Of the GP-vaccinated animals that survived challenge, a few demonstrated a modest boost in ELISA antibody titer (10- to 30-fold) when pre and postchallenge samples were compared. The surviving NP-inoculated macaques had larger boosts in ELISA antibody titers when pre- and
    postchallenge samples were compared. Some animals vaccinated with both GP and NP also demonstrated 100- to 300-fold rise in ELISA titers(Hevey et al., 1998).
  • Side Effects: Not noted.
  • Challenge Protocol: Monkeys recieved injections that expressed VEE replicons with either MBGV GP or MBGV NPor both(Hevey et al., 1998).
  • Efficacy: All animals that received VEE replicons expressing MBGV GP, either alone or in combination with MBGV NP, survived challenge with 8000 PFU MBGV without any observed signs of illness(Hevey et al., 1998).
17. Recombinant VEE Replicons expressing MBGV NP
a. Vaccine Ontology ID:
VO_0004126
b. Type:
Recombinant vector vaccine
c. Antigen
Marburg virus (MBGV) nucleoprotein (NP) (Hevey et al., 1998).
d. Gene Engineering of NP from Marburg virus Musoke
  • Type: Recombinant protein preparation
  • Description: The ORF for the glycoproteins were generated by PCR and cloned into GP-lacking VSV vectors (Daddario-DiCaprio et al., 2006).
  • Detailed Gene Information: Click here.
e. Preparation
A gene coding for a protein of interest is cloned in place of the VEE virus structural genes (Hevey et al., 1998).
f. Virulence
Without any observed signs of illness, all animals that received VEE replicons expressing MBGV GP, either alone or in combination with MBGV NP, survived challenge with 8000 PFU MBGV(Hevey et al., 1998).
g. Monkey Response
  • Host Strain: cynomolgus
  • Vaccination Protocol: Several groups of macaques were tested: a group received VRPs that expressed MBGV NP; a group received VRPs that expressed MBGV GP; a group received a mixture of MBGV GP and MBGV NP VRPs; and a group received VRPs that expressed a control antigen (influenza HA)Anti-MBGV ELISA antibody titers were monitored throughout the experiment
  • Persistence: Not noted.
  • Immune Response: Animals inoculated with replicons that expressed MBGV proteins demonstrated prechallenge ELISA titers to purified MBGV antigen. Of the GP-vaccinated animals that survived challenge, a few demonstrated a modest boost in ELISA antibody titer (10- to 30-fold) when pre and postchallenge samples were compared. The surviving NP-inoculated macaques had larger boosts in ELISA antibody titers when pre- and
    postchallenge samples were compared. Some animals vaccinated with both GP and NP also demonstrated 100- to 300-fold rise in ELISA titers(Hevey et al., 1998).
  • Side Effects: Not noted.
  • Challenge Protocol: Monkeys recieved injections that expressed VEE replicons with either MBGV GP or MBGV NPor both(Hevey et al., 1998).
  • Efficacy: All animals that received VEE replicons expressing MBGV GP, either alone or in combination with MBGV NP, survived challenge with 8000 PFU MBGV without any observed signs of illness(Hevey et al., 1998).
18. VSV-based vaccine expressing MBGV GP
a. Vaccine Ontology ID:
VO_0004136
b. Type:
Recombinant vector vaccine
c. Antigen
Marburg virus (MBGV) glycoprotein (GP) was used. A recombinant vesicular stomatitis virus (VSV) was used as a vector. The vaccine utilizes the VSVΔG/MARVGP-Musoke strain (Daddario-DiCaprio et al., 2006).
d. Gene Engineering of GP from Lake Victoria marburgvirus Musoke
  • Type: Recombinant protein preparation
  • Description: The ORF for the glycoproteins were generated by PCR and cloned into GP-lacking VSV vectors (Daddario-DiCaprio et al., 2006).
  • Detailed Gene Information: Click here.
e. Preparation
The ORF for the glycoproteins for the MARV-Musoke and the ZEBOV were generated by PCR and cloned into GP-lacking VSV vectors. Infectious clones for the VSV Indiana serotype were used (Daddario-DiCaprio et al., 2006).
f. Virulence
All animals developed high anti-MARV IgG antibody levels by the challenge time, while low levels of anti-MARV neutralizing antibodies were observed for a large percentage of animals vaccinated with VSVΔG/MARVGP-Musoke at the challenge day. Protection of the host subjects injected with the VSVΔG/MARVGP-Musoke vaccine appears to be associated with humoral response, as opposed to cellular immune response (Daddario-DiCaprio et al., 2006).
g. Monkey Response
  • Host Strain: cynomolgus macaques
  • Vaccination Protocol: Nine adult macaques were used. Seven were injected intramuscularly with the VSVΔG/MARVGP-Musoke vaccine, and two recieved VSVΔG/ZEBOVGP as experimental controls (Daddario-DiCaprio et al., 2006).
  • Persistence: Not noted.
  • Immune Response: With the use of purified virus particles for an antigen source, immunoglobulin G (IgG) antibodies against MARV were detected through an enzyme-linked immunosorbent assay (ELISA). A transient and low-level recombinant VSV viremia was detected through virus isolation on the third day after vaccination in plasma from four of the VSVΔG/MARVGP-Musoke vaccinated animals. Both the MARV-Angola-challenged control animal and the MARV-Ravn-challenged control animal developed high titers in the blood, detected by plaque assay (Daddario-DiCaprio et al., 2006).
  • Side Effects: After either vaccination with VSVΔG/MARVGP-Musoke or after the MARV challenge, none of the animals showed any evidence of clinical illness (Daddario-DiCaprio et al., 2006).
  • Challenge Protocol: All animals were challenged with either MARV-Angola, MARV-Musoke, or MARV-Ravn 28 days after immunization (Daddario-DiCaprio et al., 2006).
  • Efficacy: VSVΔG/MARVGP-Musoke vector does protect nonhuman primates against a lethal challenge with both Ravn and Angola strains of MBGV. This approach seems almost as successful as the use of VEEV MARV GP and/or VEEV MARV NP, which protected NHP against a lethal homologous challenge, but did not protect against a lethal heterologous Ravn challenge (Daddario-DiCaprio et al., 2006).
IV. References
1. Bausch et al., 2007: Bausch DG, Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert review of vaccines. 2007 Feb; 6(1); 57-74. [PubMed: 17280479].
2. Daddario-DiCaprio et al., 2006: Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. Journal of virology. 2006; 80(19); 9659-9666. [PubMed: 16973570].
3. Geisbert et al., 2010: Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. Journal of virology. 2010; 84(19); 10386-10394. [PubMed: 20660192].
4. Hevey et al., 1997: Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1997 Dec 8; 239(1); 206-16. [PubMed: 9426460 ].
5. Hevey et al., 1998: Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998 Nov 10; 251(1); 28-37. [PubMed: 9813200 ].
6. Jones et al., 2005: Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature medicine. 2005; 11(7); 786-790. [PubMed: 15937495].
7. Mohamadzadeh et al., 2007: Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nature reviews. Immunology. 2007; 7(7); 556-567. [PubMed: 17589545].
8. Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144 ].
9. Swenson et al., 2005: Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005; 23(23); 3033-3042. [PubMed: 15811650].
10. Swenson et al., 2008: Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and vaccine immunology : CVI. 2008; 15(3); 460-467. [PubMed: 18216185].
11. Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
12. Warfield et al., 2004: Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine. 2004 Sep 3; 22(25-26); 3495-502. [PubMed: 15308377 ].